Stockwinners Market Radar for October 16, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EDT Cathie Wood's ARK Investment bought 140K shares of Nurix Therapeutics today

19:04 EDT Robinhood exec sells $849K in common stock - In a regulatory filing, Robinhood disclosed that its Chief Creative Officer Baiju Bhatt sold 90K shares of common stock on October 12th in a total transaction size of $849K.

18:36 EDT Gold Resource reports preliminary Q3 sold ounces - Gold Resource reported preliminary Q3 results that includes the sale of 3,982 ounces of gold and 208,905 ounces of silver resulting in total gold equivalent ounces of 6,532. Additionally, the company sold 2,571 tons of zinc, 245 tons of copper, and 947 tons of lead. Allen Palmiere, CEO said "The quarter has presented some challenges beyond our control including decreased metal prices and the strengthening of the Mexican peso against the US Dollar. Production during the quarter was on par with the last four quarters, however average grade decreased as was expected in our 2023 mine plan. We continue to identify and implement opportunities for cost reductions and operational efficiencies. We continue to be encouraged by the positive results of our 2023 drill program at the Don David Gold Mine that demonstrate the potential to increase our resources and reserves that could lead to future increased production."

17:37 EDT NCR Voyix completes spin-off from NCR Atleos - NCR Voyix (VYX) announced that it has completed the separation of its ATM-focused business, including its self-service banking, payments & network, and telecommunications and technology businesses. The spin-off was effected through a pro rata distribution of all outstanding shares of NCR Atleos Corporation (NATL) common stock to holders of Voyix's common stock and is intended to qualify as a tax-free distribution for federal income tax purposes. Atleos common stock will begin trading "regular way" on the New York Stock Exchange under the ticker symbol "NATL" and Voyix common stock will trade "regular way" on the New York Stock Exchange under the ticker symbol "VYX" at market open on October 17, 2023. As a result of the spin-off, Voyix's focus will be on digital commerce, continuing to operate its retail, restaurant and digital banking businesses.

17:34 EDT NCR Atleos completes spin-off from NCR Voyix - NCR Atleos (NATL) announced the completion of its separation from NCR Corporation (NCR) which is now known as NCR Voyix, and Atleos' launch as an independent public company. The spin-off was effected through a pro rata distribution of all outstanding shares of Atleos common stock to holders of Voyix's common stock and is intended to qualify as a tax-free distribution for federal income tax purposes. Atleos common stock will begin trading "regular way" on the New York Stock Exchange under the ticker symbol "NATL" at market open on October 17, 2023. As a result of the spin-off, Atleos' focus will be on banking services and ATMs, including Self-Service Banking, Payments & Network and Telecommunications and Technology businesses.

17:03 EDT Marathon Oil signs five-year LNG sales agreement in Equatorial Guinea - Marathon Oil has entered into a five-year firm LNG sales agreement with Glencore Energy UK, a subsidiary of Glencore, for a portion of its equity natural gas produced from the Alba Field in Equatorial Guinea, effective Jan. 1, 2024. Separately, due to the expected arbitrage between LNG and methanol pricing, Marathon Oil expects to optimize its E.G. integrated gas operations in 2024 by redirecting a portion of Alba Unit natural gas from the local methanol facility to the LNG facility.

16:49 EDT Aldeyra says FDA noted substantive review issues related to NDA for reproxalap - In a regulatory filing, earlier this morning, the company stated: "On October 16, 2023, Aldeyra Therapeutics announced that it received minutes from a late-cycle review meeting with the U.S. Food and Drug Administration relating to the new drug application for reproxalap for the treatment of the signs and symptoms of dry eye disease. The Minutes identified substantive review issues in connection with the NDA for reproxalap. The FDA stated that "[i]t does not appear that you have data to support the clinical relevance of the ocular signs to support your dry eye indication." In subsequent communications between Aldeyra and the FDA, Aldeyra has submitted responses to the FDA that Aldeyra believes to be sufficient to mitigate the identified issues, but the FDA has not directly opined on the sufficiency of the information submitted, has no legal obligation to review the information submitted by Aldeyra, and has indicated that Aldeyra needs to conduct an additional clinical trial to satisfy efficacy requirements. As such, based on the time remaining in the NDA review cycle, the FDA may not be in the position to approve the NDA for reproxalap on or about the Prescription Drug User Fee Act target action date of November 23, 2023 or afterwards, and it may issue a Complete Response Letter and require that Aldeyra conduct additional clinical trials and submit the results of those clinical trials before the application will be reconsidered."

16:42 EDT Cerence CEO Ortmanns sells 54,212 common shares - In a regulatory filing, Cerence CEO Stefan Ortmanns disclosed the sale of 54,212 common shares of the company on October 13 at a price of $17.97 per share.

16:38 EDT NetScout falls 17% to $22.93 after cutting FY24 guidance

16:30 EDT Sempra Energy president Kevin Sagara to resign - According to a regulatory filing, on October 12, 2023, Kevin C. Sagara provided notice that he will resign as the Executive Vice President and Group President of Sempra effective December 1, 2023. Additionally, on October 12, 2023, Kevin C. Sagara provided notice that he will resign as the Chairman of the Board and as a director of Southern California Gas Company, a subsidiary of Sempra, effective December 1, 2023.

16:18 EDT CNO Financial appoints Michellen Wildin as Chief Accounting Officer - CNO Financial has named Michellen Wildin Senior VP of Accounting effective October 23, and Chief Accounting Officer effective January 1, 2024. Wildin most recently served as senior vice president, financial planning and analysis at F&G Annuities & Life, where she was a member of the company's Executive Committee. Previously, she held executive leadership positions at New York Life, including serving as vice president, corporate budget and expense analytics and CFO of NYL Direct. She has also held senior-level accounting, finance, strategy and operations roles at Aviva and ING. Wildin will succeed John Kline as CAO, who is retiring from CNO on December 31, 2023, after a 30-year career with the company. Kline will remain CAO through the end of the year to ensure a seamless transition.

16:11 EDT Pliant Therapeutics appoints Mishima Gerhart as Chief Regulatory Officer - Pliant Therapeutics announced the appointment of Ms. S. Mishima Gerhart as Chief Regulatory Officer. Ms. Gerhart will lead the Company's regulatory and quality strategies and activities.

16:07 EDT Computer Programs closes acquisition of Viewgol for $36M - CPSI "announced it has closed its acquisition of Viewgol, a provider of ambulatory revenue cycle management, analytics and complementary outsourcing services. Exclusive of synergies resulting from the transaction and incremental amortization expense related to the acquired intangible assets, Viewgol is expected to generate GAAP net income of approximately $1.5 million and Adjusted EBITDA of approximately $4.5 million in 2024. The exact timing of synergy realization is difficult to predict, and the incremental amortization expense related to the acquired intangible assets is dependent upon completion of a business valuation for purposes of allocating the purchase price; as such, the Company is unable to estimate the full impact of the transaction on CPSI's expected 2024 GAAP results at this time. CPSI intends to provide an update to full-year 2023 guidance for the combined company on its third quarter earnings call. Under the terms of the agreement, the purchase price is $36 million in cash, with an additional earnout of up to approximately $31.5 million based on a combination of achieving certain profitability metrics for 2024 and the creation of additional offshore resources supporting TruBridge. McDermott, Will, & Emery, Grant Thornton, and Willis Towers Watson acted as advisors for CPSI. Brentwood Capital Advisors, Morris, Manning, & Martin, and Meredith CPAs acted as advisors to Viewgol."

14:22 EDT Vista Outdoor to sell Sporting Products unit to Czechoslovak Group for $1.91B - The Czechoslovak Group announced that it has entered into a definitive agreement to acquire Vista Outdoor Inc.'s Sporting Products business for a total consideration of $1.91B, valuing the business at approximately 5x Fiscal Year 2024E EBITDA, including estimated standalone costs. CSG will partner with the existing management to pursue the continued growth path envisaged for the Sporting Products business over the coming years. Headquartered in Anoka, Minnesota, Vista Outdoor's Sporting Products business is a leading ammunition manufacturer in the U.S. commercial and law enforcement markets. It employs approximately 4,000 employees across its four U.S. factories and owns leading ammunition brands including CCI, Federal, HEVI-Shot, Remington and Speer. The proposed transaction would be CSG's largest acquisition to date after a long series of smaller acquisitions focused on the European market, including the acquisition of Fiocchi Munizioni in 2022. It also represents the largest acquisition in the history of the Czech defense industry. The transaction is expected to close in calendar year 2024, subject to shareholder approval, receipt of necessary regulatory approvals and other customary closing conditions. Upon closing, Sporting Products will become a wholly owned subsidiary of CSG, operating as a private company. Jason Vanderbrink will remain CEO of the Sporting Products business and the U.S. headquarters will remain in Anoka, Minnesota.

13:50 EDT New Fortress Energy sees FY24 adjusted EBITDA about $2.4B - Sees FY23 adjusted EBITDA about $1.6B. Says earnings increasing "significantly" in both size and quality. Says company focusing on long-term downstream customer earnings. Sees terminal earnings growing from about $850M this year to about $2.2B next year. Says targeting valued of FCCM could exceed $13B. Guidance taken from October 2023 Company Update presentation slides.

13:18 EDT Milner urges shareholders to disregard ISS report, vote against Abcam deal - Jonathan Milner, who identifies himself as the founder and one of the largest shareholders in Abcam plc (ABCM) with ownership of 6.16% of the company, issued the following statement in response to a report from Institutional Shareholder Service, or ISS: "I unequivocally oppose the conclusions drawn in the ISS report and its subsequent recommendation. I believe that Danaher's $24 per share offer is a stark undervaluation of Abcam's true worth. Accepting $24 per share, devoid of a strategic premium, is the wrong price at the wrong time, a move that blatantly overlooks Abcam's intrinsic value... It's important to highlight the real shareholder value that my advocacy has unlocked. While the ISS report itself acknowledges the positive impact, let's not overlook the facts: the share price soared from roughly $16 to over $20, a significant 25% rise, in the wake of my campaign being made public. I believe that voting against the transaction would be a far better outcome for shareholders, returning the company to the position it previously held as a premium-rated life sciences company with a long track record of impeccable execution and an absolute focus on shareholder value."

12:58 EDT Biocept filed voluntary petition for Chapter 7 bankruptcy relief - In a regulatory filing, Biocept disclosed that after considering strategic alternatives, the company filed a voluntary petition for relief under the provisions of Chapter 7 of Title 11 of the United States Code in the United States Bankruptcy Court for the District of Delaware on October 13. "The proceeding under the Petition is styled as 'In Re: Biocept, Inc.' As a result of filing the Petition, a Chapter 7 trustee will be appointed by the Bankruptcy Court to administer the bankruptcy estate of the company and to perform the duties set forth in Section 704 of the Code. The assets of the company will be liquidated and any claims paid in accordance with the Code," the filing stated. "Antonino Morales, Marsha A. Chandler, Bruce E. Gerhardt, Quyen Dao-Haddock, Ivor Royston, and Linda Rubinstein tendered their resignations as members of the Company's Board of Directors which resignations were effective on October 13, 2023, prior to filing the Petition. The resignations of Mr. Morales, Ms. Chandler, Mr. Gerhardt, Ms. Dao-Haddock, Mr. Royston and Ms. Rubinstein are not the result of any disagreements with the company regarding the company's operations, policies, or practices. Each of the Members have resigned due to the company's filing of the Petition which effectively eliminates the powers of the company's Board of Directors. Following the resignations of the Members, the company will have no members serving on its Board of Directors. In addition to his resignation from the company's Board of Directors, Mr. Morales tendered his resignation as the company's President and Chief Executive Officer effective on October 13," the filing added.

12:00 EDT Manchester United falls -7.9% - Manchester United is down -7.9%, or -$1.57 to $18.41.

12:00 EDT Vista Outdoor falls -23.7% - Vista Outdoor is down -23.7%, or -$7.76 to $25.04.

12:00 EDT a.k.a. Brands rises 10.2% - a.k.a. Brands is up 10.2%, or 53c to $5.73.

11:48 EDT Coca-Cola, Pernod Ricard to debut Absolut Vodka & Sprite ready-to-go cocktail - The Coca-Cola Company (KO) and Pernod Ricard (PDRDY) announced a global relationship to debut Absolut Vodka & Sprite as a ready-to-drink pre-mixed cocktail in 2024. The pre-mixed cocktail will be available in versions with Sprite and Sprite Zero Sugar, with the initial launch planned for select European countries in early 2024, including the United Kingdom, the Netherlands, Spain and Germany. "We keep consumers at the center of everything we do as we continue to develop our portfolio as a total beverage company," said James Quincey, Chairman and CEO of The Coca-Cola Company. "We are expanding in the alcohol ready-to-drink space, including products that use select brands from our core portfolio. We are excited about our new relationship with Pernod Ricard and look forward to the introduction of Absolut & Sprite."

11:25 EDT Microsoft's LinkedIn laying off 668 employees across several teams - LinkedIn Corporate Communications stated in an October update notice: "Talent changes are a difficult, but necessary and regular part of managing our business. The changes we shared with our team today will result in a reduction of approximately 668 roles across our engineering, product, talent and finance teams. While we are adapting our organizational structures and streamlining our decision making, we are continuing to invest in strategic priorities for our future and to ensure we continue to deliver value for our members and customers. We are committed to providing our full support to all impacted employees during this transition and ensuring that they are treated with care and respect." Reference Link

10:32 EDT Akso Health regains Nasdaq compliance - Akso Health received a letter from the Nasdaq Listing Qualifications Department notifying the Company that it had regained compliance with the minimum bid price requirement. On October 26, 2022, the Company received a notification that it's American Depositary Shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days, as required by Nasdaq Listing Rules of The Nasdaq Stock Market. The closing bid price of the Company's ADS was at $1.00 per share or greater from September 15, 2023 to October 10, 2023. Accordingly, the Company has regained compliance with Nasdaq Capital Market Minimum Bid Price Requirement per Listing Rule 5550(a)(2) and this matter is now closed.

10:16 EDT Spotify launches dedicated Merch Hub in app - In a company blog post, Spotify said, "When new merch drops, fans don't hesitate. We've seen that in the days and weeks after an artist releases shirts, totes, hats, vinyl, and more, fans flock to their Spotify profiles to get what's new. So to give the fans what they want-and make it easier than ever for listeners to browse and shop for merch from their favorite artists-we're unveiling a dedicated Merch Hub in the Spotify app. Sporting merch from your favorite artists is a vital part of music culture, and our new Merch hub provides personalized merch recommendations based on your listening habits. Previously, we made artist merch available from individual artist profiles, the Now Playing view, and release pages. Instead of having to browse artist by artist, this update makes it easier than ever to access all artist merch in one place. From the hub, you can browse, click on available items to learn more, and then purchase through the artist's Spotify store, powered by Shopify." Reference Link

10:02 EDT Cummins teams with industry partners on open telematics architecture - Cummins (CMI) announced its collaboration with the Eclipse Foundation, Microsoft (MSFT), and industry partners to release a new and innovative approach to develop telematics software for commercial vehicles. The Open Telematics Framework is being designed to allow companies to accelerate time to market and reduce costs. It allows each company to write their telematics application once and deploy it to any telematics hardware running the Open Telematics Framework. This write once, run anywhere approach will eliminate the complex customization and reprogramming efforts that have historically burdened telematics application developers. It also incorporates the latest cybersecurity capabilities.

10:00 EDT Guaranty Bancshares falls -6.5% - Guaranty Bancshares is down -6.5%, or -$1.83 to $26.56.

10:00 EDT Vista Outdoor falls -14.6% - Vista Outdoor is down -14.6%, or -$4.80 to $28.00.

10:00 EDT Trinity Industries rises 5.4% - Trinity Industries is up 5.4%, or $1.19 to $23.10.

09:50 EDT L Catterton completes acquisition of Thorne HealthTech - L Catterton announced the completion of its acquisition of Thorne HealthTech. The tender offer to purchase all of the issued and outstanding shares of Thorne's common stock in exchange for $10.20 per Share, net to the seller in cash, without interest and less any required withholding taxes, expired as scheduled at one minute past 11:59 p.m., Eastern Time, on October 12, 2023 and was not extended. L Catterton previously announced that, as of the Expiration Time, 52,596,517 Shares were validly tendered and not validly withdrawn in the Offer, representing 97.3% of the issued and outstanding Shares as of the Expiration Time. In accordance with the terms of the Offer, L Catterton and its affiliate, Healthspan Merger Sub, Inc., accepted for payment all such Shares that were validly tendered and not validly withdrawn pursuant to the Offer. Following completion of the Offer, L Catterton completed the acquisition of Thorne through the previously planned second-step merger. Thorne's common stock will be delisted from the Nasdaq Global Select Market and deregistered under the Securities Exchange Act of 1934, as amended.

09:47 EDT Manchester United falls -8.9% - Manchester United is down -8.9%, or -$1.77 to $18.21.

09:47 EDT Vista Outdoor falls -16.3% - Vista Outdoor is down -16.3%, or -$5.36 to $27.44.

09:47 EDT Cemex rises 6.7% - Cemex is up 6.7%, or 41c to $6.57.

09:46 EDT Prothena trading resumes

09:41 EDT Prothena jumps 11% to $49.05 after Bloomberg says exploring sale

09:37 EDT Jehoshaphat Research short R1 RCM, says stock 'practically uninvestible' - In a recently published report, Jehoshaphat Research says it is short R1 RCM. "We believe its financial accounting is so misrepresentative, its corporate governance so surprisingly bad, and the reflexivity of its business model so misunderstood that its stock is practically uninvestible today. Our forensic accounting concerns have been reinforced by conversations we've had with former RCM and Cloudmed employees. We see idiosyncratic downside beginning to play out in the next several months as accounting games reach a natural exhaustion point on an overleveraged company -- and the lockup on 33% of RCM's shares expires in two months. We believe that it's entirely reasonable that the stock will revisit the lows of $7 per share following Q3 2022 earnings," it reads. Shares of R1 RCM are down about 2% to $12.95 in Monday morning trading. Reference Link

09:32 EDT R1 RCM down 4% in early trading after Jehoshaphat short call

09:24 EDT Mullen Automotive 'on track' to produce 150 Class 3 EV trucks through December - Mullen Automotive announces a commercial vehicle production update for both Class 3 EV cab chassis trucks and Class 1 EV cargo vans. As previously forecasted, the Company is currently on track to produce 150 Class 3 EV trucks through December 2023. The Company is also on track to begin Class 1 EV cargo van production and deliveries in Q4 2023. Mullen's Class 3 production plans for the remainder of 2023 are on schedule with an estimated 150 vehicles projected to be produced and delivered to Randy Marion Automotive Group. The first ten Class 3 vehicles were delivered to RMA on Sept. 28, 2023. In total, Mullen expects to deliver more than 150 Class 3 vehicles to Randy Marion this year and to fulfill the balance of the 1,000 Class 3 vehicle purchase order in calendar year 2024, where the production schedule has been set at 850 trucks. As previously reported, Class 3 production capacity at the Tunica facility is currently planned at 3,000 annually per shift, allowing units to be added to the schedule as additional customers are confirmed. Class 1 EV cargo van production is on track to begin in Q4 2023 with the Company producing an estimated 300 vehicles. The total Class 1 EV cargo van production for CY 2024 is planned for 6,000 vehicles allowing the RMA purchase order to be fulfilled. Class 1 production capacity at the Tunica, Mississippi, facility is currently planned at 10,000 annually per shift. As electric vehicle adoption rates increase, Mullen intends to add a second shift for Class 1 production, which will increase capacity to 20,000 total vehicles per year. In summary, the following reflects total planned commercial vehicle production for calendar years 2023 and 2024: 2023 CY estimated commercial vehicle production: 150 Class 3 EV cab chassis trucks; 300 Class 1 EV cargo vans. 2024 CY estimated commercial vehicle production: 850 Class 3 EV cab chassis trucks; 6,000 Class 1 EV cargo vans.

09:22 EDT Vuzix announces orders from three Tier-1 aerospace and defense contractors - Vuzix announced it has recently received and partially delivered against additional follow-on and new design orders from three Tier-1 aerospace and defense contractors with which it has been working. The revenue associated with these OEM orders is in the mid six-figure range. The Company expects to receive additional NRE orders for subsequent phases from some of these contractors. Once final customer-accepted product designs have been achieved, they could ultimately lead to production program orders. In at least one case, these deliveries are pre-production components. For the first customer, Vuzix is delivering a customized waveguide-based optics engine that is intended to be used in head borne systems designed for military applications. For the second customer, a global Tier-1 aerospace and defense firm, Vuzix has received a follow-on order for additional pre-production units for their customized avionics waveguide-based head mounted display system, as well as a new design order for a different waveguide-based display. For the third customer, a US-based leader in technologically advanced and intelligent solutions for the global aerospace and defense industry, Vuzix is continuing to deliver assets for the Phase 2 development of a cost efficient, lightweight heads-up display, or HUD, for a unique HMD based application.

09:13 EDT Ericsson selected by Appalachian Wireless - Ericsson announced that Appalachian Wireless, an East Kentucky Network, or EKN, company, has chosen Ericsson for a multi-year Radio Access Network, or RAN, modernization project to bring world-class 5G technologies to underserved communities in Appalachia. The partnership marks a step forward in connectivity and technological advancement for the mountainous region, where Appalachian Wireless is the sole network provider for many households and businesses. Appalachian Wireless aims to be the first regional carrier to implement 5G standalone to bridge the digital divide in rural America.

09:10 EDT Micron announces Micron 7500 NVMe SSD - Micron Technology announced the Micron 7500 NVMe SSD for data center workloads. The 7500 SSD is the world's only mainstream data center SSD to feature 200+ layer NAND, utilizing Micron's 232-layer NAND and enabling up to 242% better random write performance than competitive drives.1 The SSD also delivers sub-1 millisecond latency for 6x9s quality-of-service in mainstream drives, creating a new class of SSDs perfectly suited to deliver the consistency required in the cloud. The Micron 7500 SSD is designed to meet the demands of storage-intensive data center workloads, such as artificial intelligence, databases, content delivery, real-time analytics, social media platforms, cloud computing and virtualization. Its remarkable QoS and performance provide rapid, reliable responsiveness for these demanding workloads. For example, the drive improves RocksDB performance by up to 2.1 times versus competitive SSDs.

09:09 EDT Immix Biopharma completes third NXC-201 engineering batch - Immix Biopharma announced the successful completion of its 3rd engineering batch of BCMA-targeted chimeric antigen receptor T, CAR-T, cell therapy NXC-201 at its U.S. manufacturing site. "We believe the completion of our 3rd U.S. engineering batch represents an important threshold to demonstrate our U.S. manufacturing capability for NXC-201 IND submission in the United States," said Ilya Rachman, M.D. PhD, Chief Executive Officer of Immix Biopharma. "NXC-201's 100% observed overall response rate across 9 relapsed/refractory AL Amyloidosis patients, where NXC-201 has received orphan drug designation from the FDA, makes this an important milestone in bringing NXC-201 to U.S. patients."

09:07 EDT Check Point launches Check Point Horizon Playblocks - In the face of rapidly spreading cyberattacks and the consistent persistence of attackers using multiple vectors, Check Point Software Technologies launches Check Point Horizon Playblocks, a security automation and collaboration platform that automatically contains attacks and prevents them from spreading, all powered by collaboration between security people, processes and technologies. Horizon is Check Point's prevention-first security operations security suite, which includes the Managed Detection/Prevention and Response SOC service, the Extended Detection/Prevention and Response SOC platform and now Playblocks, the security collaboration platform for security teams.

09:06 EDT PubMatic, FreeWheel announce integration of PubMatic's activate - PubMatic announced a new integration partnership with FreeWheel, a global technology platform for the television advertising industry. Through this enhanced integration, PubMatic's Activate will now have direct access - through FreeWheel - to premium publisher connected television ad inventory. This new partnership will bring about two key benefits and new capabilities for the TV ad ecosystem: Ad buyers working with PubMatic will now have an enhanced and streamlined ability to transact across a larger and more diversified pool of premium CTV ad inventory. FreeWheel publishers will have access to unique campaign budgets only available through Activate. In doing so, the two companies aim to provide increased interoperability, efficiency and transparency for buyers and sellers of premium CTV ad inventory at scale.

09:05 EDT Neuberger Berman urges Lionsgate to eliminate dual-class share structure - Neuberger Berman announced that it has submitted a proposal calling on the Board of Directors of Lions Gate Entertainment to take all reasonable and necessary steps to eliminate the dual-class share structure of the company. The Proposal will be presented to shareholders for a vote as Proposal 6 at the company's 2023 Annual General and Special Meeting of Shareholders, which is scheduled for November 28, 2023. Neuberger Berman, on behalf of its clients, has been an investor in Lions Gate since 2016. The Proposal requests that the Board take all reasonable and necessary steps to ensure that each outstanding share of common stock has one vote. Lions Gate's dual-class structure has existed since the company's merger with Starz in 2016. Neuberger Berman strongly believes that the planned separation of the Starz business should be implemented in a manner that positions the company that will hold the remaining Starz business and the company that will hold the separating Studio business with governance structures that align the voting and economic interests of all shareholders.

09:05 EDT GrowLife releases Kind Coffee Cooperative product - GrowLife announced the release of its newest product, Kind Coffee Cooperative. Developed by RPG Coffee in partnership with Bridgetown Mushrooms, a wholly owned subsidiary of the Company, the new product will benefit kindness.org and is now available to pre-order.

09:04 EDT Mobilicom announces it has secured two follow-on orders - Mobilicom announced it has secured two follow-on orders, including one order from a large Tier-1 customer. One of Mobilicom's current customers, a Tier-1 global leader in the defense and aerospace market, and one of the largest drone manufacturers in the world, placed an order for Mesh Networking to be embedded into a new platform solution. The customer had previously purchased SkyHopper Datalinks. Another current Mobilicom customer, a maker of remote controlled weapons stations, placed a repeat order for more Mobile Ground Control Stations. "Security, defense, and highly targeted military operations are increasingly deploying autonomous, uncrewed, and aerial systems. Recent events underscore the need for preparedness. Mobilicom is proud to have a key role in bringing the most advanced cybersecure drone systems to those who secure peace and protect the innocent," stated Mobilicom CEO and Founder Oren Elkayam.

09:03 EDT Fortress Biotech subsidiary announces option agreement with City of Hope - Helocyte, a subsidiary company of Fortress Biotech, announced that it executed an exclusive option agreement with City of Hope for patent rights to use Triplex, a cytomegalovirus vaccine, in combination with cytomegalovirus-specific, Anti-Human Immunodeficiency Virus Chimeric Antigen Receptor T Cells for the treatment of adults living with HIV. Triplex was initially developed by City of Hope, one of the largest cancer research and treatment organizations in the United States, and exclusively licensed to Helocyte in 2015. Additionally, the California Institute for Regenerative Medicine recently awarded a $11.3 million grant to City of Hope to fund a Phase 1 clinical trial. The Phase 1 trial is expected to enroll up to 12 healthy individuals living with HIV-1 on stable anti-retroviral therapy who have maintained viral suppression for at least 48 weeks. The study will include three dose-escalating cohorts, along with an expansion cohort. Other cohorts will include further vaccination of subjects with Triplex to drive continued proliferation of the CAR. The trial will initially enroll at City of Hope and University of California at San Diego.The clinical study will build upon preclinical data published in Molecular Therapy - Methods & Clinical Development which demonstrated the potential efficacy of combining a CMV vaccine and CMV/HIV CAR T cell therapy to eradicate HIV. To date, the engineering of T cells to express HIV-specific CAR T cells has failed to demonstrate meaningful clinical benefits. This is believed to be due in part to the effectiveness of highly active ART, which reduces HIV viral load to a level that prevents the activation of CAR T cells.

09:01 EDT Neuronetics announces publication on best practices for TMS treatment outcomes - Neuronetics announced that clinical findings from the NeuroStar Outcomes Registry are published in the premier journal in the field of neuromodulation, Brain Stimulation: Basic, Translational, and Clinical Research in Neuromodulation. The data reveal a robust association between the number of treatment sessions received and improved depression outcomes, providing actionable evidence for clinicians prescribing transcranial magnetic stimulation therapy to treat major depressive disorder. Findings from this study of over 7,000 patients demonstrate that patients who received a full course of 36 TMS sessions had an 82% greater improvement in remission rate and a 43% greater improvement in response rate compared to patients who ended their TMS course with fewer than 30 sessions. Historically, TMS therapy is discontinued by either the patient or the practitioner at various points of treatment, but the findings published in Brain Stimulation demonstrate that stopping treatment before 36 sessions is associated with significantly reduced treatment effectiveness. In addition to the significant dose response for a majority of patients, the analysis from the study also revealed that some patients who have a slower initial response may benefit from extended treatment beyond 36 treatments.

09:01 EDT Caterpillar names Joseph Creed as COO - Caterpillar announced that Joseph Creed, group president of Energy & Transportation, has been appointed to the newly created position of COO, effective Nov. 1, 2023. In this newly created position, Creed will report to Jim Umpleby, chairman and CEO. Creed joined Caterpillar in 1997 and has held numerous positions of increased responsibility across multiple divisions of Caterpillar.

08:57 EDT Twin Vee PowerCats' Aquasport begins shipping boats from Tennessee factory - Twin Vee Powercats announced that its subsidiary, AquaSport Co., is now shipping boats from its factory in White Bluff, Tennessee. Aquasport currently builds seven different models at its 150,000-square-foot manufacturing facility in Tennessee, ranging from 21-feet to 30-feet.

08:53 EDT Wearable Devices joins Khronos Group as a voting right member - Wearable Devices announced that the Company has joined Khronos Group's OpenXR working group as a member with voting rights. OpenXR seeks to simplify alternate reality/virtual reality software development and enable applications to reach a wider array of hardware platforms without having to port or rewrite code. Guy Wagner, Chief Scientist Officer and Co-Founder of Wearable Devices, commented, "We're excited to join Khronos Group's OpenXR working group and contribute to the development of true cross-platform XR applications alongside industry leaders. XR is rapidly gaining popularity in the tech industry, and Wearable Devices is uniquely positioned with our technology to define the input standard for spatial computing and extended reality devices. We look forward to contributing to the OpenXR platform and broadening the scope and capabilities of extended reality experiences."

08:51 EDT Sellas Life Sciences announces initial topline Phase 2a data of SLS009 - SELLAS Life Sciences announced positive initial topline data at the 45 mg dose level from its ongoing Phase 2a clinical trial of its novel and highly selective CDK9 inhibitor, SLS009, in combination with venetoclax and azacitidine in patients with relapsed/refractory acute myeloid leukemia who did not respond or stopped responding to venetoclax-based therapies. Topline data for the recommended Phase 2 dose is expected later this quarter. A total of five patients with r/r AML who failed venetoclax-based therapies have been enrolled to date at the 45 mg dose level. The first patient enrolled in the study achieved a complete response, remains alive and is currently in the fifth month of treatment after relapsing on venetoclax, and the second patient is alive and in the fourth month of treatment. All patients enrolled were alive at the time of their last follow-up and four continue treatment. Anti-leukemic effects have been observed in all patients without any significant safety issues to date. Patients with AML that fail venetoclax-based therapies have limited treatment options and a poor prognosis with a median overall survival of approximately 2.5 months. "This initial outcome that includes a complete response, anti-leukemic activity in all patients, good safety profile across the patients and indications of extended survival for our enrolled patients still continuing treatment, we believe opens multiple registrational opportunities for SLS009. We will be exploring these options in the coming weeks as we treat patients with the recommended Phase 2 dose, 60 mg, in this study," said Angelos Stergiou, MD, ScD h.c., President and Chief Executive Officer of SELLAS. "While these results are early, they are extremely encouraging and consistent with the Phase 1 study results, and further strengthen our initial proposition that the addition of CDK9 inhibition in combination with BCL-2 inhibition and hypomethylating agents could provide patients with a triple hit to increase response rates and survival outcomes without sacrificing safety and tolerability due to the specificity of SLS009. We look forward to providing additional updates this quarter from this study."

08:50 EDT BlackSky wins Air Force research contract - BlackSky won a U.S. Air Force Research Laboratory AFWERX Direct to Phase 2 contract, funded by the Space Development Agency, to build an automated target recognition service that will gather and combine radio frequency and electro-optical satellite sensor data to track mobile assets in real-time and securely distribute actionable intelligence to remote devices and analysts worldwide.

08:49 EDT TOP Ships announces compliance with NASDAQ minimum bid price requirement - TOP Ships announced that NASDAQ notified the Company that it has regained compliance with the minimum bid price requirement for the Nasdaq Capital Market, set forth in Nasdaq Listing Rule 5550(a)(2).

08:48 EDT Cuentas signs LOI to acquire WHEN Group - Cuentas signed a letter of intent to acquire control of WHEN Group, pending Nasdaq and shareholder approval and other specified conditions, through a share exchange with WHEN's principal shareholder, leaving Cuentas uniquely debt-free and well positioned to grow its mobile and FinTech lines. The WHEN Group was founded by Israeli engineers and international professionals with deep background in Cyber security and data threat remediation in both government and private sectors. From business and personal privacy to fin-tech security, WHEN has been developing solutions that utilize advanced pattern recognition and AI to create a security screening environment that can detect and defend against a range of threats and attacks on telecom, banking, and other communication infrastructure. Upon closing of the acquisition, Cuentas intends to begin integrating WHEN's portfolio of Cyber Security solutions into the Cuentas Mobile Platform as well as offering WHEN's advanced solutions to Cuentas' fintech partners. Cuentas' Management has been working with WHEN to identify immediate opportunities to provide WHEN solutions not only to the CUENTAS mobile platform, but also to the businesses and industries that Cuentas serves in the U.S. and around the world. Additionally, the parties are planning on deploying WHEN's proprietary software to protect families concerned with external cyber threats at home, enabling the monitoring of a child and his environmental behavioral patterns that will alert parents to potential tragedies caused by cyberbullying, pedophiles, other predators, and depression / state of mind. In consideration of the acquisition of the 75% stake in WHEN, Cuentas will issue to UCG, Inc. the principal shareholder of WHEN, such number of common shares of CUEN which will represent on the date of issuance 50% of Cuentas' issued and outstanding capital, in exchange for UCG's stake in WHEN. Subject to the terms of the agreement, WHEN Group management, including Major Gen. Danny Yatom, a former Director of Israeli Mossad, and current President of WHEN, and Giora Rosensweig, CEO with major experience in cyber security and artificial intelligence, will be joining the Cuentas Board of Directors and Executive Management. While the companies will initially continue to operate independently, management from both teams believe the synergies between the companies can pave the way to even deeper relationships. Cuentas' Board of Directors has approved the transaction and the Companies expect to complete the transaction this year. The closing is contingent on several factors, including without limitation, the approval of Nasdaq and the shareholders of Cuentas approving the transaction.

08:46 EDT Rail Vision says operations 'remain unaffected' by Israel situation - Rail Vision expressed its deepest sympathies and heartfelt condolences to all those affected by the recent tragic events in Israel. "We are deeply saddened by the distressing situation unfolding in our country," stated Shahar Hania, CEO of Rail Vision. "We empathize with every individual impacted and strongly condemn the acts of violence that have occurred. We are confident in the strength of our people and our nation. Our focus remains on serving our communities, employees, and customers and contributing to a peaceful and prosperous future for all." Despite the challenging circumstances, Rail Vision has ensured that its operations remain unaffected. Rail Vision is dedicated to ensuring the safety and well-being of its employees, customers, and the communities it serves. The Company has robust contingency plans to maintain business continuity and is working closely with local authorities and stakeholders to monitor ongoing events.

08:45 EDT Celestica launches DS5000 800GbE switch - Celestica aunched its DS5000 high-performance 800GbE switch, delivering speed and agility for data center and enterprise-class access deployments. We are seeking approval to release the DS5000 into the open source domain as the first Open Compute Project-inspired commercial 800G Ethernet switch contribution to the OCP Networking group.

08:44 EDT Lixte Biotechnology, NKI, Oncode Institute expand collaboration - LIXTE Biotechnology announced that it has signed an agreement to expand its collaboration with the Netherlands Cancer Institute, NKI, and Oncode Institute to study drug synergies of LIXTE's lead clinical compound, LB-100, with immunotherapy in various cancers. The new agreement also will seek to find synthetic lethal combinations in additional cancer types. The two-year extension agreement follows successful collaboration during the past two years to identify the most promising drugs to be combined with LB-100 for treating colon cancer, as well as to identify the specific molecular mechanisms underlying the identified combinations in order to provide a rationale to test these combinations in clinical trials. Bas van der Baan, the recently appointed Chief Executive Officer and President of LIXTE, added, "The collaboration with Prof. Bernards and his team provides us with unique insights in our efforts to identify promising therapy combinations for LB-100 and a more targeted approach to cancer treatment."

08:42 EDT Allogene Therapeutics appoints Geoffrey Parker as CFO - Allogene Therapeutics has appointed Geoffrey Parker as Executive Vice President, Chief Financial Officer. Mr. Parker will oversee the Company's financial operations and business strategy and will serve as a member of the Leadership Team. Before joining Allogene, Mr. Parker served as Chief Operating Officer, Chief Financial Officer and Executive Vice President of Tricida.

08:40 EDT Iovance Biotherapeutics announces clinical data for lifileucel at ESMO Congress - Iovance Biotherapeutics announced the publication of an abstract reporting clinical data for lifileucel which will be presented at the European Society for Medical Oncology ESMO Congress 2023, October 20-24, 2023 in Madrid, Spain. The abstract reports outcomes of a subset of 12 patients with advanced mucosal melanoma treated with lifileucel in the pooled consecutive cohorts from the C-144-01 trial. All patients had progressed on or after immune checkpoint inhibitor therapy. Patients with mucosal melanoma, which is rare and difficult to treat, have worse outcomes after anti-PD-1 therapy compared to patients with other melanoma subtypes. The ORR assessed by an independent review committee using RECIST v1.1 was 50%. At median study follow-up of 35.7 months, median duration of response was not reached, median progression free survival was NR, and median overall survival was 19.4 months. Treatment emergent adverse events were consistent with known safety profiles of lymphodepleting chemotherapy and interleukin-2.

08:38 EDT Maris-Tech expands activity in U.S. defense market, appoints Emanuel to board - Maris-Tech announced significant steps toward expansion of its activity in the U.S. market. The Company announced the appointment of Adam Emanuel of Emanuel & Associates, Inc., located in Washington, D.C., to Maris-Tech's Advisory Board and the Company's partnership with him and Altagrove, a defense and space manufacturing company that delivers smart and innovative technology solutions to create competitive customer advantages, located in Virginia, to facilitate the marketing of its products in the U.S. governmental and defense market.

08:36 EDT Terns Pharmaceuticals announces Phase 1 trial design of TERN-701 - Terns Pharmaceuticals announced the U.S. Food and Drug Administration's clearance of the Company's Investigational New Drug application and the design of the CARDINAL Trial, Terns' global Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of TERN-701 in participants with chronic myeloid leukemia. TERN-701 is the Company's proprietary, allosteric BCR-ABL tyrosine kinase inhibitor, designed to target the BCR-ABL myristoyl pocket. "Allosteric BCR-ABL inhibitors comprise a novel class of therapy for CML that has been shown to have superior efficacy and improved safety compared to active-site inhibitors in prior studies. We are particularly pleased with our Phase 1 trial design for TERN-701 as it will recruit chronic CML patients who experienced treatment failure on at least one prior second-generation TKI. This will allow us to offer a novel investigational allosteric inhibitor to CML patients in as early as their second line of therapy, where there are currently no approved allosteric inhibitors," said Emil Kuriakose, MD, chief medical officer-oncology at Terns Pharmaceuticals.

08:36 EDT WeWork names David Tolley as Chief Executive Officer - WeWork announced that David Tolley has been named Chief Executive Officer. Tolley has served as a WeWork Board Member since February 2023 and as interim Chief Executive Officer since May 2023. "WeWork's ability to define and lead an evolving world of work is a direct result of the tenacity and hard work of our employees who have built an exceptional product, member experience, and brand," said Tolley. "As companies continue to rethink their office strategies, and demand for flexible office space continues to grow, WeWork offers a unique suite of solutions that empower entrepreneurs and companies of all sizes to collaborate together, evolve and thrive." Tolley most recently served as Chief Financial Officer of Intelsat S.A. from 2019 to 2022. Over the course of his career, Tolley has also served as Chief Financial Officer of OneWeb, was a private equity partner at Blackstone from 2000 to 2011 and prior to that was a Vice President in the Investment Banking Division of Morgan Stanley...WeWork also announced that current WeWork Board member, Paul Keglevic, was appointed Chair of the Board of Directors, effective September 1.

08:34 EDT Comera Life Sciences presents SQore platform technology data - Comera Life Sciences Holdings will present research demonstrating Comera's SQore platform capabilities in the development of subcutaneous monoclonal antibody formulations at the PODD: Partnerships in Drug Delivery conference in Boston, Mass. Yuhong Zeng, Ph.D., Director of Formulation at Comera, will present data from Comera's SQore platform which is designed to transform intravenous biologics such as monoclonal antibodies nto subcutaneous formulations. Comera's SQore platform has been successfully tested with over 40 mAbs, with viscosity reductions of up to 85%. Comera uses the SQore platform to identify the driving forces for high viscosity and select excipients that inhibit attractive protein-protein interactions to lower viscosity. Comera is also presenting data from a preclinical study, previously published in the Journal of Pharmaceutical Sciences, that found that a caffeine excipient reduced viscosity of the monoclonal antibody ipilimumab without any adverse impact on antibody pharmacokinetic properties. The addition of one or more excipients, such as caffeine, selectively interrupts intermolecular interactions to reduce viscosity of high concentration mAb formulations.

08:33 EDT Alignment Healthcare California, North Carolina Medicare receive high scores - Alignment Healthcare announced that its California Medicare Advantage HMO - which represents roughly 89% of its MA membership - has maintained an overall 4- out of 5-star rating from the Centers for Medicare & Medicaid Services for 2024, marking its seventh consecutive year as a 4-star or greater plan. Additionally, its North Carolina HMO achieved an overall 4.5- out of 5-star rating for 2024, its second year eligible for rating. "Our noteworthy star ratings reflect the high quality of our plans and service, but we are not done," said John Kao, founder and CEO of Alignment Healthcare. "We are committed to ensuring that all our members receive five-star quality care and service, which is why we continually push to elevate and enhance our member experience. At the heart of everything we do is our seniors, and we will continue to listen closely to our members to deliver the care they need and deserve."

08:33 EDT Imax announces $13M debut for 'TAYLOR SWIFT: THE ERAS TOUR' - IMAX hit a high note at the global box office this weekend with a $13M debut for "TAYLOR SWIFT: THE ERAS TOUR", making it the biggest IMAX opening ever for a film by a musical artist - concert or documentary. The highly anticipated release from the global pop icon earned an impressive $11M in North America on IMAX screens - good for 11% of the overall Domestic gross - in addition to $2M oversees.

08:31 EDT Spectral AI adds additional clinical sites to DFU study - Spectral AI announced the addition of seven clinical sites that are currently enrolling to support the development of its diabetic foot ulcer application for the DeepView Wound Imaging System. The proprietary technology combines multi-spectral imaging and AI technology to provide clinicians with an immediate healing assessment of DFU's for more accurate and timely diagnosis and therapeutic intervention. Participating investigators and clinical sites include: Dr. Tony Alleman, MD, University of Tennessee Health Science Center; Dr. Ian Barron, DPM, Gentle Foot Care Hilliard and Gentle Foot Care Grove City; Dr. Stephen Frania, DPM, Foot and Ankle Specialist of Ohio; Dr. Vladimir Zeetser, DPM, Premium Podiatry and Wound Care; Dr. Charles Ananian, DPM, New Hope Podiatry Group; Dr. Karl Fulkert, DPM, Worthington Foot and Ankle.

08:31 EDT Silo Pharma announces results on SPU-21 peptide against Rheumatoid Arthritis - Silo Pharma announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis, RA. "The purpose of this study was to expand our investigation of our patented SPU-21 cyclic peptide beyond preclinical animal models to human tissue assays," said Eric Weisblum, Chief Executive Officer of Silo Pharma. "The data shows strong binding affinity to the main stromal cells in human RA synovial tissue, indicating the peptides' preferential interaction with the inflamed synovial tissue for disease-suppressive effects. We look forward to our next data readout for SPU-21 by the end of the year or early 2024." The University of Maryland, Baltimore is Silo Pharma's collaboration partner for SPU-21 development. In addition to SPU-21, Silo Pharma holds a license agreement with UMB for a central nervous system homing peptide targeting multiple sclerosis and other rare neurological diseases designated

08:28 EDT National Mortgage partners with TRUE to advance digital mortgage ecosystem - National Mortgage Insurance, a subsidiary of NMI Holdings, has partnered with TRUE, the leader in lending intelligence, to streamline operational capabilities and expand homeownership opportunities by unleashing the power of AI-driven automation. The partnership combines National MI's private mortgage insurance platform that facilitates homeownership opportunities for borrowers who need down payment support with TRUE's Data Intelligence product and unique AI-powered document and data processing capabilities. By integrating TRUE's AI technology into its digital mortgage ecosystem, National MI expects to reduce its document and data processing times while dramatically accelerating loan decision timelines. By working together, National MI and TRUE will provide critical relief to all three groups by delivering seamless, faster loan responses while reducing the burden and cost of manual reviews and increasing data quality. "We have been on a mission from day one to help more people experience the stability and security of homeownership," said Ari Gross, CEO and co-founder of TRUE. "Working together with National MI to help lenders make informed lending decisions by harnessing the power of AI is an important step toward our goal. We are not only providing the latest lending decision technology; we are helping to fulfill the American dream of homeownership more efficiently."

08:26 EDT Perspective completes recruitment for first patient cohort in VMT01 trial - Perspective Therapeutics announced the completion of recruitment for the first patient cohort in its Phase 1/2a dose escalation study of 212Pb-VMT01, its targeted alpha-particle therapy, in development for the treatment of MC1R-positive metastatic melanoma.

08:22 EDT Entera Bio reports rapid PD response, consistent PK data for PTH mini tablets - Entera Bio presented 2 posters at the Annual Society of Bone and Mineral Research 2023 Annual Meeting held on October 13-16, 2023 in Vancouver, BC, Canada. The lead drug candidate of Entera's EBP05 formulation, EB613 is currently being developed as the first once-daily oral anabolic therapy for the treatment of osteoporosis. Abstract Title: First Oral PTH Tablet Treatment for Osteoporosis Demonstrates Rapid Pharmacodynamic Effect on Plasma Levels of Endogenous PTH. A Phase 1 study comparing oral EB613, subcutaneous hPTH 20 g and a new generation of Entera's oral peptide delivery platform is ongoing. One of the first objectives of this study is to rapidly evaluate the pharmacodynamic effects of Entera's oral PTH tablets. This analysis relates to Entera's lead formulation. Additional data on new formulations will be released later in 2023. An increase in plasma ionized calcium should result in decreased secretion and plasma concentrations of endogenous PTH. Thus, a reduction in plasma PTH should provide an early indication of the systemic exposure and pharmacologic activity of Entera's oral PTH tablets. In the study, the mean percentage of endogenous plasma PTH 120 minutes after dosing was 59.2%, 54.3%, and 52.3% for EB613 1.5 mg, 2.5 mg and Forteo, respectively; and showed consistent effects across other early PD markers such as serum calcium, phosphorus, and 1,25-dihydroxyvitamin D. Abstract Title: Pharmacokinetic Profile of EBP05/EB613 Oral Teriparatide Tablets in Women of Post Menopausal Age Versus Young Adult Men. This retrospective analysis compares the pharmacokinetic profile of EBP05 in healthy young males versus female patients of menopausal age with hypoparathyroidism. A single administration of the same dose, 2.25 mg oral PTH, in healthy young men and women of postmenopausal age resulted in a median Cmax of 425 pg/ml vs 521 pg/ml, and a median AUC of 157 pg*hour/ml vs 158 pg*hour/ml respectively

08:19 EDT Jack Henry and Member Driven Technologies extend partnership, no terms - Member Driven Technologies or MDT and Jack Henry announced that they have extended their partnership, continuing to work together to help credit unions improve member service and efficiencies through leading solutions and services. Through the partnership, MDT hosts the Symitar core processing system from Jack Henry to provide a private cloud alternative for core processing and IT needs. "MDT is a trusted leader in helping credit unions of all sizes launch and optimize digital technology to enhance the member experience and effectively compete," said Shanon McLachlan, President of Credit Union Solutions for Jack Henry. "By extending our successful, long-term partnership, MDT will further our technology modernization strategy, helping credit unions across the country leverage sophisticated cloud-based and digital tools to create a competitive differentiator."

08:17 EDT Ultragenyx announces program, updates on GTX-102, UX701, setrusumab - Ultragenyx Pharmaceutical will provide updates on its development pipeline, including setrusumab for osteogenesis imperfecta, GTX-102 for Angelman syndrome, UX701 in Wilson disease and the rest of the company's gene therapy portfolio at an Analyst Day held in New York City and by webcast. Analyst Day Updates. "UX143 monoclonal antibody for Osteogenesis Imperfecta: Interim Phase 2 data from the Phase 2/3 Orbit study show statistically significant decrease in annualized fracture rates following at least 6 months of treatment." Data presented at the American Society for Bone and Mineral Research 2023 Annual Meeting show that treatment with setrusumab reduced the annualized fracture rate by 67% and this reduction was associated with continuing large and meaningful improvements in bone mineral density. Setrusumab was generally well tolerated with no drug related serious adverse events reported and no reports of drug-related hypersensitivity. The company plans to provide updated Phase 2 data next year. "GTX-102 antisense oligonucleotide for Angelman syndrome: Data from the extension cohorts in the Phase 1/2 study show clinically meaningful improvements in multiple domains." Quantitative data show improvements across multiple clinical domains compared to natural history data, where available, and clinical changes were associated with quantitative changes in EEG. Long term data showed patients who stopped and restarted treatment reacquired previously gained developmental skills when they were re-dosed with the current regimen. There have been no additional treatment-related SAEs, including lower extremity weakness, since November 2022. Data from the dose expansion cohorts on at least 20 patients who have been on therapy for at least 6 months is anticipated in the first half of 2024. "UX701 AAV gene therapy for Wilson disease: Four of five patients in the lowest-dose cohort of the Phase 1/2/3 Cypress 2+ study show improvements in tapering standard of care": Four out of 5 patients in the low-dose Cohort 1 have had reductions in urinary copper and are tapering off of chelators and/or zinc therapy, including 2 of 3 earlier treated patients in the Cohort that are now completely off standard therapy. UX701 has been generally well tolerated with no treatment-related SAEs. The seamless study is expected to complete dosing of all 3 dose cohorts in Stage 1 at the end of 2023 and these data are expected in the first half of 2024. Company also provided update on other late-stage gene therapy candidates: DTX401 AAV gene therapy for Glycogen Storage Disease Type Ia: The Phase 3 GlucoGene study was fully enrolled in the first quarter of 2023 and the company plans to provide preliminary data in the first half of 2024. UX111 for Sanfilippo syndrome: The pivotal Transpher A study has been fully enrolled and the company plans to meet with the FDA in the fourth quarter of 2023. DTX301 AAV gene therapy for Ornithine Transcarbamylase Deficiency: The Phase 3 Enh3ance study is expected to complete enrollment in the first half of 2024.

08:15 EDT Corbus Pharmaceuticals presents pre-clinical characterization of CRB-701 - Corbus Pharmaceuticals announced that a poster characterizing the pre-clinical validation of CRB-701, a next generation antibody drug conjugate targeting nectin-4 was presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in Boston on October 14th 2023. The poster, titled Development of CRB-701: A novel site-specific Nectin-4 targeting ADC, provides an overview of the pre-clinical development and validation of the differentiating features of CRB-701, including: Site specific conjugation chemistry and a stable linker that leads to low payload release in plasma. A novel nectin-4 targeting monoclonal antibody with improved speed of internalization and a pharmacokinetic profile that can support Q3W dosing in the clinic. A safety profile supports dosing at higher ADC exposures relative to enfortumab vedotin. CRB-701 demonstrates statistically significant tumor growth inhibition in preclinical models that express mid- and high-levels of nectin-4, similar to EV. However, in a low expression model, CRB-701 also exhibited statistically significant tumor growth inhibition in a primary bladder tumor model with low nectin-4 expression where EV did not. CRB-701 has a longer half-life than EV and is being dosed on a Q3W schedule in the clinic. When dosed at 1.2 mg/kg CRB-701 demonstrated notably lower levels of free MMAE.

08:14 EDT Enphase Energy launches IQ8 Microinverters in India - Enphase Energy announced that it has started shipping IQ8 Microinverters, with peak output AC power of 480 W, in India to support newer high-powered solar modules. "Enphase actively works with installers to ensure we're meeting the needs of their businesses and customers as part of our commitment to expand our product offerings worldwide," said Aaron Gordon, vice president and general manager of the microinverter business unit at Enphase Energy. "IQ8 Microinverters feature our most advanced technology to date that's compatible with the wide range of solar modules on the market today, and we're pleased to support the newer high-powered solar modules in India."

08:12 EDT Acrivon Therapeutics presents data on AP platform, ACR-368 OncoSignature Assay - Acrivon Therapeutics announced data highlighting its AP3 approach to identify and evaluate biomarkers for its OncoSignature assay designed specifically to predict sensitivity to ACR-368, the company's selective small molecule inhibitor targeting CHK1 and CHK2, currently in registrational-intent Phase 2 clinical trials. The data were presented in two posters at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston this past week. The poster titled "Identification of Biomarkers Predictive of Sensitivity to the CHK1/2 Inhibitor ACR-368 Using High-Resolution Phosphoproteomics and Development of an ACR-368-Tailored Patient Responder Identification 3-Marker Test, ACR-368 OncoSignature" showed data leveraging the company's AP3 approach, including ultra-high resolution, quantitative mass spectrometry-based phosphoproteomics profiling combined with proprietary approaches to identify three classes of functionally orthogonal candidate biomarkers specifically predictive of sensitivity to ACR-368. Biomarker candidates were initially evaluated through pathway reconstitution and in cellular functional assays, after which they were assembled into the ACR-368 OncoSignature assay for further functional validation. The quantitative multiplex in situ ACR-368 OncoSignature assay was used to provide a direct readout of the activity state of the drug target signaling axis regulated by ACR-368 and that the tumor depends on for dysregulated CHK1/2-driven DNA repair and replication stress. These data support the use of the company's ACR-368 OncoSignature assay in its ongoing registrational-intent Phase 2 clinical trials, and demonstrate the distinctive, practical application of the company's AP3 platform. The poster titled "Validation of the OncoSignature Assay, an ACR-368-Tailored Response-Predictive Quantitative Multiplexed Immunofluorescent Assay for Prediction of Sensitivity to the CHK1/2 Inhibitor ACR-368 in Individual Patients with Cancer" provided data validating the ability of the AP3-derived ACR-368-specific OncoSignature assay to predict tumor response to ACR-368 in multiple blinded, prospectively-designed preclinical studies, including two separate studies on pretreatment tumor biopsies from past Phase 2 clinical trials in patients with ovarian cancer and in tumor types predicted sensitive to ACR-368, including endometrial cancer. In the two pretreatment tumor biopsy studies, the ACR-368 OncoSignature test was overall able to segregate responders from non-responders with high accuracy and enrich for responders, achieving an overall response rate of 47% and 58% with strong statistical significance. Endometrial and bladder cancers were identified as new tumor types predicted sensitive to ACR-368 in 30-40% of cases. Data in the poster confirmed the predicted efficacy in genetically non-modified, PDX models of endometrial cancer, and further demonstrated that the ACR-368 OncoSignature assay could predict sensitive from insensitive models with an AUC of 0.88 in blinded studies.

08:10 EDT Constellation Energy has 'key role' in $1B clean hydrogen hub awarded by DOE - Constellation "is a major participant in the MachH2 hydrogen hub recently selected for up to $1B by the Department of Energy DOE as part of the bipartisan Infrastructure Investment and Jobs Act. Constellation will use a portion of the hub funding to build the world's largest nuclear-powered clean hydrogen production facility at its LaSalle Clean Energy Center in Illinois. The project will produce an estimated 33,450 tons of clean hydrogen each year and create thousands of good-paying jobs. Constellation estimates its LaSalle clean hydrogen facility will cost about $900 million, with a portion of the MachH2 award offsetting the project's cost.

08:09 EDT Kratos Defense announces MoU between Technical Directions, Boeing - Kratos Defense & Security Solutions (KTOS) announced a Memorandum of Understanding, MoU, between Technical Directions, TDI, a business unit within Kratos Unmanned Systems Division, and Boeing (BA) for the TDI-J85 turbine engine to provide propulsion for the Powered Joint Direct Attack Munition, JDAM. Boeing's Powered JDAM combines a 500-pound ordnance, the conventional JDAM guidance kit, with a wing kit and a Kratos TDI-J85 engine to deliver high-end range at an affordable price. The cost savings is in part due to the low-cost turbine engine technology developed and enhanced by TDI over four decades. Powered JDAM will provide low-cost stand-off capability against land and maritime threats. Leveraging the JDAM family of weapons, it is designed to be produced at scale, exportable to any of the 35 JDAM partner nations, at a cost-point that enables affordable mass. "We are proud that Boeing has selected our TDI-J85 engine for the Powered JDAM system. Incredible potential exists for this long-range, precision strike capability," said Joseph Kovasity, Senior Vice President for TDI. "At Kratos TDI, we have been singularly focused on producing small, low-cost, military-grade turbine engines at quantity in the United States with U.S. suppliers and partners. With the Kratos acquisition of TDI, we have substantially invested in manufacturability for production scale resulting in an incredibly high engine performance-to-cost ratio, while ensuring we can meet the large quantity deliveries predicted for the Powered JDAM system and program."

08:07 EDT Consolidated Communications acquired by Searchlight and BCI for $4.70 per share - Consolidated Communications Holdings announced that it has entered into a definitive agreement to be acquired by affiliates of Searchlight Capital Partners and British Columbia Investment Management Corporation "BCI" in an all-cash transaction with an enterprise value of approximately $3.1B, including the assumption of debt...Under the terms of the Agreement, Searchlight and BCI will acquire all of the Consolidated common stock not already owned by Searchlight for $4.70 per share in cash. The purchase price represents a premium of approximately 70% to the closing price of the Company's common stock through April 12 the last trading day prior to the submission of Searchlight and BCI's initial non-binding proposal to the Company's Board of Directors and a premium of approximately 33% to the closing price of the Company's common stock as of October 13. The transaction implies a 9.6x multiple on the Company's LTM EBITDA, pro forma for the previously disclosed sales of certain non-core operations, including the expected sale of Washington assets, as of June 30, . The proposed transaction has been unanimously approved by a special committee of independent and disinterested directors of the Board advised by independent legal and financial advisors, formed to evaluate and consider the proposal and other potential strategic alternatives. The Board of Directors of the Company, following recusals of directors affiliated with Searchlight and BCI, has approved the proposed transaction on the unanimous recommendation of the Special Committee.

08:06 EDT Banxa Holdings chairman Domenic Carosa to retire, Holger Arians to succceed - After a 10-year tenure as Founder and Chairman of the Board, Domenic Carosa has decided to retire from his position as Chairman and resign from the Board effective immediately. In his place, Holger Arians, the CEO, has been appointed to the Board and will assume the role of Director & Chairman of the Board. Furthermore, Matthew Cain, non-executive director, has decided to retire and will be stepping down from the Board effective immediately. Finally, Leigh Travers will join the Board as a non-executive director, representing Dominet Digital Investments, a company associated with outgoing Chairman Domenic Carosa.

08:05 EDT Medigus says Revoltz secures partnership with HLS distributor - Medigus announced that Revoltz Ltd. which is 19.9% held by Charging Robotics Ltd., wholly subsidiary of Fuel Doctor Holdings, has entered an exclusive distribution agreement in the United State for its advanced micro-mobility EVs, with a leading distributor operating in the homeland security (HLS) and law enforcement sector. As part of the agreement, the distributor committed to purchase a minimum of 500 units of PORTO, Revoltz' state-of-the-art micro-mobility vehicles in the coming year.

08:04 EDT Rain Oncology confirms receipt of unsolicited proposal from Concentra - Rain Oncology confirmed that it has received an unsolicited proposal from Tang Capital on behalf of Concentra Biosciences to acquire all outstanding shares of common stock of Rain for $1.25 per share in cash, plus a contingent value right representing the right to receive 80% of the net proceeds payable from any license or disposition of Rain's programs. Consistent with its fiduciary duties, Rain's Board of Directors, in consultation with its independent financial and legal advisors, will carefully review and evaluate the proposal from Concentra Biosciences. Rain's stockholders are advised to take no action at this time.

08:03 EDT Ambrx Biopharma reports safety, efficacy data from Phase 1/2 APEX-01 trial - Ambrx Biopharma announced that two abstracts detailing updated safety and efficacy data from the ongoing Phase 1/2 trial, APEX-01, evaluating ARX517 for metastatic castration-resistant prostate cancer were made available as part of the 2023 European Society of Medical Oncology Congress 2023 meeting, taking place in Madrid, Spain, October 20-24, 2023. APEX-01 opened for enrollment in July 2021, and is the only ongoing clinical trial in the United States targeting PSMA with an antibody-drug conjugate. APEX-01 is a first-in-human, open-label, dose escalation and dose expansion study enrolling patients with mCRPC whose tumors have progressed on at least two prior FDA-approved treatments, including at least one second-generation androgen receptor pathway inhibitor. The inclusion criteria included one of the following: PSA progression defined by a minimum of two rising PSA values, radiographic progression by RECIST v1.1 or disease progression by the presence of new bone lesions. The two clinical abstracts submitted to ESMO regarding the APEX-01 trial used a cutoff date of May 3, 2023. Ambrx will provide more mature data with a later data cutoff date, including a significantly greater number of patients from the dose expansion portion of APEX-01, in the ESMO posters and in its associated press release. Title: APEX-01: First-in-human Phase 1/2 study of ARX517, an anti-prostate-specific membrane antigen antibody-drug conjugate, in patients with metastatic castration-resistant prostate cancer: Abstract Highlights: In dose escalation patients treated via intravenous infusion every 3 weeks at putative therapeutic doses greater than or equal to2.0 mg/kg: 7 out of 9 patients experienced a greater than or equal to50% PSA reduction; 3 out of 3 patients in Cohort 6; 2 out of 3 patients in Cohort 7; 2 out of 3 patients in Cohort 8; 5 out of 5 patients experienced a greater than or equal to50% ctDNA reduction; 3 out of 3 patients in Cohorts 6; 2 out of 2 patients in Cohort 7; Cohort 8 data not available; In 24 dose escalation patients treated from 0.32 mg/kg to 2.88 mg/kg ARX517 was well-tolerated at all doses; No treatment-related SAEs observed; No DLTs observed; Four Grade 3 treatment-related adverse events were reported in Cohort 5, Cohort 7 and Cohort 8. Title: ARX517, a next generation anti-PSMA antibody drug conjugate, demonstrates notable stability and pharmacokinetic profile in the ARX517 Phase 1/2 clinical trial. Abstract Highlights: The pharmacokinetics population consisted of 21 dose escalation patients having received ARX517 across all dose levels; ARX517 exhibited virtually overlapping total antibody and ADC PK concentration-time curves at all dose levels tested indicating strong stability of the ADC with minimal premature payload release; A long ADC terminal half-life of ~6-10 days was observed at doses greater than or equal to 1.4 mg/kg, thereby maximizing drug exposure over a dosing cycle of 3 weeks; Low concentrations of pAF-AS269 were observed at all dose levels and appeared slowly in the circulation, with Cmax observed approximately 7 days after administration

08:02 EDT Halozyme reports results from clinical study of ENHANZE - Halozyme Therapeutics announced positive results of a clinical study demonstrating subcutaneous administration of 10 mL of a representative biologic product co-formulated with its ENHANZE drug delivery technology, in approximately 30 seconds. In the study, the biologic was delivered with Halozyme's proprietary high-volume auto-injector (HVAI) in healthy volunteers. The injection was delivered successfully to all 23 participants and was well tolerated. In the study, a representative biologic, immunoglobulin 10%, was delivered to 23 healthy volunteers. The primary endpoint of the study was achieved with all subjects receiving the completed dose with HVAI, demonstrating that 10 mL of a representative biologic product can be rapidly delivered using Halozyme's ENHANZE and HVAI technologies. Data Highlights include: 96% of participants stated that they would be willing to receive the injection again; 90% of participants indicated feeling either no pain or mild pain immediately after injection; and Erythema, swelling, and induration were generally minimal to mild and resolved by 90 minutes or less.

07:46 EDT LQR House delivers inaugural order to Costco - LQR House announced that through its custom marketing campaign and strategic efforts, Von Payne Whiskey is now displayed on the shelves of the retail giant, Costco.

07:44 EDT Almaden Minerals reports on developments on Ixtaca mineral title applications - Almaden Minerals reports on two recent court decisions, both relating to the submission issued by Mexico's Ministry of the Economy to the second district court in Puebla State in February 2023. As reported on February 22, April 13, and September 14, 2023, Economia made the Submission to the District Court seeking to deny the two mineral title applications which were first made by Almaden in 2002 and 2008. The Submission claims that the applications contain technical faults, despite Economia's previous statements to the contrary and its acceptance of the mineral title applications and grant of the mineral titles in 2003 and 2009. By alleging technical faults in the mineral title applications, Economia appears to be arbitrarily seeking to deny the grant of the mineral titles and avoid the indigenous consultation ordered by the February 2022 decision of Mexico's Supreme Court. Such consultation would be welcomed by both the Company and surrounding community members. The two court decisions reported are summarized below: The Federal Appeals court dismisses all of the appeals filed by the Parties, including those of the Company and supporting community members, and rules the Submission is compliant with the 2022 decision of the SCJN, since the SCJN decision did not formally prevent Economia from reviewing the technical aspects of the mineral title applications; The TCC ruling also does not address the validity of the Submission and therefore safeguards the Company's right to challenge the substance and legality of the Submission through the Mexican Federal Administrative Court; As follow-up to the press release of September 14, 2023, the TFJA has now granted a definitive injunction in relation to the Submission, which prevents Economia from releasing the mineral rights covered by Almaden's mineral title applications to third parties while the trial continues, anticipated to last 18 months. By way of background, the two mineral titles previously owned by Almaden which covered the Ixtaca project were the subject of a lawsuit against the Mexican government asserting that the Mexican mining law is unconstitutional. In April 2019, the District Court issued a decision that Mexico's mining law is unconstitutional because it fails to include provisions requiring consultation of indigenous communities before granting mineral titles. This decision was appealed by Mexican authorities and the Company, as an affected third party, with the appeals being heard by the SCJN. In early 2022, the SCJN ruled that the Mexican mineral title law is constitutional, but that Economia should have provided for a consultation procedure with relevant indigenous communities prior to issuing the mineral titles. The SCJN ordered Economia to declare Almaden's mineral titles ineffective and to then conduct indigenous consultation prior to re-issuing them. The SCJN decision provided guidance to Mexican authorities regarding the procedures required to be followed by those authorities in the follow-up to its decision and performance of indigenous consultation. The decision also clarified that unless there is a significant impact on the rights of an indigenous community caused by the granting of the mineral title, such as relocation or something similar, title issuance is not dependent upon the consent of any indigenous community. The District Court was responsible for ensuring that the SCJN decision was properly implemented. As noted above, on February 22, 2023, Economia made the Submission to the District Court seeking to deny the two mineral title applications, and on April 13, 2023, Almaden reported that the District Court ruled that the Submission formally complied with the SCJN decision. However, the District Court ruling appeared to rely heavily on Economia's Submission regarding the Company's 2002 and 2008 title applications, and in its decision the District Court did not provide arguments to address the Company's challenge of the Submission. Almaden and local community members filed separate appeals of this decision to the TCC. In parallel, Almaden initiated a case in the TFJA to contest the substance and legality of the Submission. In the court decisions announced today, the TCC has denied all Parties' appeals of the District Court decision and ruled that the Submission formally complies with the SCJN decision, since in the exercise of its jurisdictional freedom Economia could determine the inadmissibility of the mineral title applications as the SCJN decision did not limit Economia's jurisdiction when reviewing technical aspects of the mineral title applications. Also, the TCC confirmed that the subject matter of the appeal was limited to verifying Economia's compliance with the SCJN decision, rather than analysing the substance or legality of the Submission itself. Almaden has been advised that as a consequence, the TCC safeguarded the Company's rights to pursue a separate legal process to examine the substance and legality of the Submission. This TCC ruling is final. In addition, the TFJA has now granted a definitive injunction to Almaden's Mexican subsidiary, Minera Gorrion which prevents Economia from releasing the mineral rights covered by the Company's mineral title applications while the administrative trial regarding the substance and legality of the Submission continues. Economia has five days from the time of its notification of this decision to appeal this ruling. Almaden has been advised that so long as the TFJA trial continues, its mineral title applications from 2002 and 2008 remain in place thus preserving the Company's preferential rights to the mineral title. The TFJA process is expected to take approximately 18 months.

07:41 EDT Theratechnologies finalizes amendments of credit agreement with Marathon - Theratechnologies has finalized all documentation giving effect to the amendments to certain of the terms and conditions of its credit agreement dated July 20, 2022, as amended from time to time, with certain funds and accounts for which Marathon Asset Management, L.P. acts as investment manager. The amendments to the Credit Agreement provide for, inter alia: revising the minimum liquidity requirements for all times following October 31, 2023 to be between $15 million and $20 million, based on thresholds for adjusted EBITDA over the most recently ended four fiscal quarters; revising the minimum revenue requirements to be based on adjusted EBITDA-based targets instead of quarterly revenue-based targets, beginning with the quarter ending November 30, 2023; deleting the prohibition against the Company having a going concern explanatory paragraph in the opinion of the independent registered public accounting firm of the Company that accompanies the Company's annual report. As disclosed in its September 25, 2023, press release, in consideration of the proposed amendments, the Company agreed to pay an amount equal to $600,000, or 100 basis points calculated on the outstanding principal amount of the funded debt as of October 16, 2023, which such amount was added to the outstanding principal amount of the funded debt as payment in kind ; and reprice the exercise price of the common share purchase warrants held by Marathon to $0.575 per share from $1.45 per share. Following the share consolidation completed on July 31, 2023, the exercise of four Warrants and the payment of $2.30 are required to subscribe to one common share of Theratechnologies, for up to a maximum issuance of 1,250,000 common shares. The Warrants can be exercised until February 27, 2030.

07:39 EDT Beyond Cancer presents preclinical data for UNO therapy at AACR-NCI-EORTC - Beyond Cancer announced promising new preclinical data further supporting the company's novel Ultra-High Concentration Nitric Oxide, UNO, therapy for various types of solid tumors as a single agent and in combination with checkpoint inhibitors. These data were presented in two posters at the American Association for Cancer Research-National Cancer Institute-European Organisation for Research and Treatment of Cancer, AACR-NCI-EORTC, International Conference on Molecular Targets and Cancer Therapeutics 2023, which was held October 11th - 15th in Boston, Massachusetts. Abstract #: 35782 describes a pooled analysis of preclinical studies utilizing 50,000 or 100,000 ppm UNO for 5 or 10 minutes in combination with 4-5 doses of 5 or 10 mg/kg Anti-mPD-1. The analysis showed that the combination therapy resulted in statistically significant primary and secondary tumor-free mice at day 75 compared with mice treated with anti-mPD-1 alone. In addition, the analysis showed a statistically significant improvement in survival during the same time period. Abstract #: 35688 represented an ex vivo analysis of T-cell response following administration of a 5-minute treatment of 50,000 or 100,000 ppm UNO in combination with 2-5 doses of 5 or 10 mg/kg Anti-CTLA-4. At day 5, mice treated with the combination therapy showed a statistically significant increase in the expression of proliferating T-helper cells versus mice treated with anti-mCTLA-4 alone. Mice treated with the combination therapy also demonstrated increases in cytotoxic T-cells, as well as a significant increase in active T-helper cells as represented by IFN responses. At day 7, mice treated with either UNO alone or in combination with Anti-mCTLA-4 had significant increases in the expression of central memory T-cells. Further, at day 55, in cured mice treated with the combination therapy, the expression of the antigen specific T-cells was nearly statistically significant relative to untreated mice. A separate experiment carried out to day 100, demonstrated a statistically significant expression of antigen specific cytotoxic T-cells relative to naive mice.

07:37 EDT Brainsway announces publication of study data on Deep TMS for depression - BrainsWay announced the publication of new real-world post-marketing data demonstrating the efficacy of accelerated Deep Transcranial Magnetic Stimulation, Deep TMS, for the treatment of major depressive disorder, MDD. The compelling results were published in the peer-reviewed journal, Psychiatry Research, in an article titled, "Real-World Efficacy and Safety of Various Accelerated Deep TMS Protocols for Major Depression." Deep TMS utilizes specially designed H-Coils to stimulate deep and broad cortical regions associated with depression. The standard FDA-cleared Deep TMS protocol involves one treatment session per day, five days a week for 4 weeks, followed by a maintenance period. However, there has been recent interest in "accelerated" dosing schedules which involve multiple sessions each day to allow for quicker overall treatment time. Data collected using this approach to treat depression was compiled from clinical sites and analyzed in this study. Key findings from this post-marketing study included: Accelerated Deep TMS led to an 80% response rate and a 51% remission rate across all dosing schedules, using the most rated scale; There was no statistical difference in outcomes seen between the various accelerated dosing schedules, which varied between 2, 3, 5 or 10 Deep TMS sessions per day; Subjects undergoing protocols involving more than 2 sessions per day responded and/or remitted typically within 3-5 days, and the durability of treatment was substantial. "We are firmly dedicated to identifying innovative solutions for various mental health disorders with the goal of transforming lives," said Colleen Hanlon, Ph.D., Vice President of Medical and Clinical Affairs of BrainsWay. "An accelerated protocol could potentially work better with some patients' schedules. While additional research is necessary to fully understand the benefits of accelerated protocols, these initial results are certainly promising as they suggest outcomes can be achieved which are comparable to those resulting from longer, traditional protocols."

07:36 EDT Cognition Therapeutics presents new data at CTAD conference - Cognition Therapeutics announced upcoming presentations from studies of CT1812, the Company's lead candidate for the treatment of adults with early, mild and moderate Alzheimer's disease at the Clinical Trials on Alzheimer's Disease, CTAD, conference being held October 24-27, 2023 virtually and in person in Boston, MA. An oral late-breaking presentation will also discuss the Phase 2 study design of the company's ongoing START study, which is enrolling adults with early Alzheimer's disease. Participants in START will be permitted to be on stable background therapy with lecanemab, an FDA-approved anti-amyloid antibody. "The approval of monoclonal antibody therapies against amyloid beta protofibrils represents an important milestone in Alzheimer's drug development, but industry experts agree that combination treatments will likely be required to achieve greater impact on the disease," explained Anthony Caggiano, MD, Ph.D., Cognition's CMO and head of R&D. "To this end, we and our colleagues at the National Institute of Aging and the Alzheimer's Clinical Trials Consortium made the strategic decision to allow participants to enroll in the ongoing Phase 2 START study who are being administered lecanemab. We believe this will allow us to assess the benefit of CT1812 in real-world conditions."

07:35 EDT Silvercorp Metals reports Q2 gold production up 105% from last year - Silvercorp Metals reports production and sales figures for the Q2. The Company expects to release its Q2 unaudited financial results on November 9 after market close. Q2 operational results include: gold production of 2,458 ounces, an increase of 105% over Q2 of FY23; silver equivalent production of approximately 1.8M ounces; and lead and zinc production of approximately 16.1M pounds and 4.6M pounds, an 11% and 23% decrease over Q2 FY23, respectively.

07:35 EDT CTO Realty Growth sells community shopping center in Texas for $14.8M - CTO Realty Growth announced the closing of the sale of Westcliff Shopping Center, a 134,750 square foot single community shopping center located in Fort Worth, Texas. The Property was sold for $14.8 million, representing an exit cap rate of 5.2% and generating a loss on sale of approximately $0.9 million. The Company expects to utilize the sales proceeds as part of a Section 1031 like-kind exchange. Following the completion of the 1031 Exchange, the Company intends to use available proceeds to repay a portion of the outstanding balance under its revolving unsecured credit facility. With the closing of this transaction, the Company has approximately $36.1 million of proceeds held in 1031 restricted cash accounts.

07:33 EDT AppTech Payments to acquire FinZeo, terms not disclosed - AppTech Payments has signed a definitive agreement for the purchase of Alliance Partners, LLC, the owners of FinZeo, a software development company centered around the movement of money, nationally and globally. This transaction aligns with AppTech's recent initiatives, reinforcing the company's commitment to developing innovative technologies, driving global expansion through strategic partners, and exploring M&A opportunities to create revenue synergies and expand product offerings. FinZeo was founded in 2018 and is dedicated to delivering innovative payment and banking technology solutions for businesses of all sizes. By integrating the FinZeo platform, AppTech believes it can augment its technology offerings, furnishing users with cutting-edge tools accessible via online portals or through an API. FinZeo's API enables AppTech to efficiently integrate with software providers and Independent Software Vendors, facilitating rapid technology implementation. The onboarding process for ISVs will be streamlined with the support of video tutorials, a dedicated customer center, and a sandbox API environment. With the assimilation of FinZeo, AppTech evolves into a Payment Facilitator, propelling the company's aggregation model. The management of AppTech believes that the closing of this strategic acquisition can help propel enhancements to AppTech's Commerce platform, clearing the project roadmap and positioning the Company at the forefront of technological progress. FinZeo enables capabilities to now span all banking-as-a-service products, such as virtual accounts and cards, and encompass money transmitter licenses, thus complementing AppTech's existing product suite. This transaction is intended to be completed by October 31, 2023, subject to the satisfaction of customary closing conditions.

07:32 EDT ContraFect announces FDA clearance of CF-370 IND application - ContraFect announces that the U.S. Food and Drug Administration, FDA, has notified the company that it has completed the safety review of its Investigational New Drug, IND, application for CF-370 for the treatment of hospital-acquired bacterial pneumonia, HABP, and ventilator-associated bacterial pneumonia, VABP, and concluded that the company may proceed with its Phase 1 clinical study. This milestone is significant for ContraFect and historic in the field of non-traditional antibacterial therapies, as CF-370 will be the first engineered lysin therapeutic targeting Gram-negative pathogens to enter a human clinical trial. CF-370 has demonstrated potent in vitro activity against Pseudomonas aeruginosa, Acinetobacter baumannii, Klebsiella pneumoniae, Escherichia coli and Enterobacter cloacae and across numerous animal models of pneumonia, including efficacy against multi-drug resistant strains. ContraFect is a global innovator in the discovery and development of DLAs, leading the field with an intellectual property portfolio which includes thirty U.S. patents, one hundred and fifty-four issued foreign patents and two hundred and forty-six pending U.S. and international patent applications. The company's discovery platform and functional expression library are designed to enable the construction and identification of novel therapeutic proteins that can penetrate the outer membrane of Gram-negative bacteria, resulting in lysis and prokaryotic cell death. CF-370 represents the first product candidate to be developed using the company's proprietary technologies.

07:20 EDT Beamr Imaging announces latest beta service powered by NVIDIA NVENC - Beamr announced its latest beta service, which is now powered by NVIDIA NVENC, coupled with Beamr's Content Adaptive Bitrate technology, offering accelerated storage optimization at scale. Since its IPO, Beamr has moved from completion of its technology's integration with NVIDIA GPUs to availability of its solution on AWS in 6 months. This third Beta version has a new user interface for manual video optimization, an API for large-scale automation, and support for NVIDIA GPUs for large-scale, cost-effective automation at high speed on AWS. Beamr is committed to democratizing video optimization and making it available to everyone at low cost. Today, Beamr is unveiling its pricing plan for the launch of the Beamr SaaS platform. Users can process video content at the incredibly competitive rate of only $0.05 for each GB processed. Beamr believes this pricing model ensures affordability and flexibility for content providers of all sizes. Beamr customers can anticipate substantial savings, with an average of a 30% reduction in storage and networking costs, all while benefiting from highly affordable processing rates. To further enhance the customer experience, Beamr has introduced a savings calculator tool, empowering users to forecast their storage and networking savings accurately.

07:18 EDT Xtract One lands contracts with three multi-national companies - Xtract One announces its next phase of growth with targeted and strategic international expansion. Xtract One has landed contracts with three significant multi-national companies, including a global entertainment organization, for deployment of SmartGateway at their venue. This three-year deal, totaling over $5.1 million includes hardware, software, installation, and support components. Using that initial customer deal as a launchpad into global markets, the Company has taken a strategic and intentional approach of partnering with key global customers and establishing agreements with resellers and install partners to support and help scale into these markets. These strategic partnerships have generated further interest from similar entertainment organizations, professional sports franchises, and other international organizations.

07:15 EDT Streamline Health appoints Bryant Reeves as interim CFO - The Company announced the appointment of Bryant "B.J." Reeves as the Company's Interim Chief Financial Officer, effective October 13, 2023. Mr. Reeves will succeed Thomas J. Gibson as Interim Chief Financial Officer of the Company, and Mr. Gibson will remain available to the Company through October 31, 2023 to ensure an orderly transition. Reeves joined Streamline Health in 2020 and has held various roles in finance and accounting and most recently served as the Company's Chief of Staff.

07:14 EDT Streamline Health appoints Benjamin Stilwill as CEO - The Company also announced certain management changes and transitions in connection with the strategic restructuring. Effective October 13, 2023, Benjamin Stilwill has been appointed to the position of Chief Executive Officer of the Company. Mr. Stilwill will succeed Wyche T. "Tee" Green, III as Chief Executive Officer of the Company, with Mr. Green transitioning to the role of Executive Chairman at that time. Following his transition to the role of Executive Chairman, Mr. Green has agreed to forego a salary and will continue to serve as a director and as Chairman of the board of directors of the Company. Mr. Stilwill most recently served as Streamline's President and, prior to that, as CEO of the Company's eValuator business.

07:13 EDT Streamline Health suspends guidance related to Booked SaaS ACV - The Company is suspending previous guidance related to Booked SaaS ACV and anticipates providing updates on future expectations in conjunction with the release of its fiscal third quarter 2023 financial results.

07:12 EDT Freeline to present new clinical data for FLT201 at ESGCT Congress - Freeline Therapeutics announced that it will present new clinical data from its ongoing Phase 1/2 GALILEO-1 trial of FLT201, its adeno-associated virus gene therapy candidate, in patients with Gaucher disease Type 1 at the European Society of Gene & Cell Therapy, ESGCT, 30th Annual Congress being held October 24-27, 2023 in Brussels, Belgium. The oral presentation will include data on safety, tolerability, GCase enzyme activity, substrate, and hemoglobin and platelet levels from the first two patients treated with FLT201.

07:11 EDT EyePoint appoints Duty to board of directors, promotes Elston to EVP - EyePoint Pharmaceuticals announced the appointment of Stuart Duty to its Board of Directors and the promotion of George Elston to Executive Vice President, EVP. Stuart Duty is an experienced financial executive with over 30 years of experience in finance and investment banking. Duty was most recently a Senior Managing Director at Guggenheim Securities, LLC. Elston joined EyePoint in 2019 as Chief Financial Officer & Head of Corporate Development.

07:10 EDT Novo Nordisk to acquire ocedurenone from KBP Biosciences for up to $1.3B - Novo Nordisk A/S and KBP Biosciences PTE., Ltd. announced that Novo Nordisk has agreed to acquire ocedurenone for uncontrolled hypertension with potential application in cardiovascular and kidney disease from KBP Biosciences for up to $1.3B U.S. dollars. Ocedurenone is an orally administered, small molecule, non-steroidal mineralocorticoid receptor antagonist that is currently being examined in the phase 3 trial CLARION-CKD in patients with uncontrolled hypertension and advanced chronic kidney disease, or CKD. The CLARION-CKD phase 3 trial has been initiated in the US, Europe and Asia with the first patient dosed at the end of 2021 and will continue as planned with a total of more than 600 patients expected to be randomised by more than 150 sites. Novo Nordisk expects to initiate phase 3 trials in additional cardiovascular and kidney disease indications in the coming years, aiming to maximize the full potential of ocedurenone. "We look forward to adding ocedurenone to our pipeline as it will complement our current development programmes in cardiovascular disease and chronic kidney disease. This deal is closely aligned with our strategic focus on expanding from our core in diabetes into other serious chronic diseases, including through novel drug modalities, to help many more patients living with unmet medical needs," said Camilla Sylvest, executive vice president, Commercial Strategy & Corporate Affairs at Novo Nordisk. The closing of the acquisition is subject to receipt of applicable regulatory approvals and other customary conditions and is expected to happen before the end of 2023. The transaction will not impact Novo Nordisk's previously communicated operating profit outlook for 2023 or the ongoing share buy-back program. Novo Nordisk will fund the acquisition from financial reserves.

07:09 EDT OTC Markets welcomes Grupo Bimbo to OTCQX - OTC Markets Group announced Grupo Bimbo has qualified to trade on the OTCQX Best Market. Grupo Bimbo S.A.B. de C.V. upgraded to OTCQX from the Pink market.

07:07 EDT NuCana presents data from ongoing NuTide:701 study of NUC-7738 - NuCana announced a presentation on the ongoing NuTide:701 study of NUC-7738 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 that took place October 11-15, 2023 in Boston, Massachusetts. The NuTide:701 study is in the Phase 2 part investigating NUC-7738 both as a monotherapy in solid tumors and in combination with the anti-PD-1 therapy pembrolizumab in patients with metastatic cutaneous melanoma. All patients had exhausted standard available therapies. NUC-7738 has been well tolerated both as a monotherapy and in combination with pembrolizumab. Encouraging signs of efficacy, including tumor volume reductions and prolonged time on treatment have been observed in both the monotherapy and combination cohorts. In the combination cohort of melanoma patients, who had all been previously treated with anti-PD-1 based therapy, numerous patients achieved tumor volume reductions and prolonged time on treatment. One patient who was refractory to the anti-PD-1 plus anti-CTLA-4 therapy combination of nivolumab plus ipilimumab achieved a 50% reduction in tumor volume on NUC-7738 plus pembrolizumab and remains on treatment. Seven of the eleven patients recruited to date remain on treatment. Patient tumor biopsy data showed that, following treatment with NUC-7738 plus pembrolizumab, expression of PD-1 was reduced and CD8+ T-cells increased, indicating that NUC-7738 may have the ability to potentiate immunotherapy. This finding provides a rationale as to why NUC-7738 plus pembrolizumab may be effective in patients who have progressed on prior immunotherapy.

07:05 EDT Wesdome Gold Mines reports Q3 gold production of 27,760 ounces - Anthea Bath, President and CEO commented, "As expected, combined production in Q3 was slightly lower than Q2 as a result of planned mill maintenance at Eagle River. At Kiena, ramp development continues to track ahead of schedule, positioning us well to develop and access higher grade reserves in H1 2024. We are also pleased to announce that towards the end of the quarter, we received the necessary permit required to drive an exploration ramp at Presqu'ile. This authorization allows us to assess the continuity of the mineralization and test the down plunge extension of the deposit. With an uptick in production expected in the fourth quarter, our year to date performance of 87,119 ounces has us tracking to the mid-point of our 110,000 - 130,000 ounce guidance range. The Company also announces that it has issued its fourth annual Environmental, Social, and Governance Report, which provides an overview of the company's ESG strategies, policies, risk management approach and commitments. The report also outlines year-over-year Company performance from 2018-2022 across these key sustainability objectives. We are proud of our accomplishments over the last year and remain committed to strong sustainability performance in the future."

07:04 EDT Timken to acquire iMECH, terms undisclosed - Timken has reached an agreement to acquire Engineered Solutions Group, based in Houston, Texas. iMECH manufactures thrust bearings, radial bearings, specialty coatings and other components primarily used in the energy industry. The business employs approximately 70 people and projects revenue of approximately $30M for calendar year 2023. Timken will fund the transaction with a combination of cash on hand and its existing revolving credit facility. The deal is subject to customary closing conditions and is expected to close in the fourth quarter. Timken will fund the transaction with a combination of cash on hand and its existing revolving credit facility. The deal is subject to customary closing conditions and is expected to close in the fourth quarter.

07:03 EDT Ginkgo Bioworks and Zenfold Sustainable Technologies announce collaboration - Ginkgo Bioworks and Zenfold Sustainable Technologies, a company focused on developing and manufacturing specialty ingredients using sustainable technologies and precision fermentation, announced a collaboration to leverage Ginkgo Enzyme Services in its effort to discover an enzyme critical to the manufacturing of veterinary products. This partnership aims to replace traditional chemical processes in veterinary active ingredient production with a sustainable biological method.

07:02 EDT Lyra Therapeutics appoints Ronan O'Brien as CLO - Lyra Therapeutics announced the appointment of Ronan O'Brien, as Chief Legal Officer, effective October 16, 2023. Most recently Mr. O'Brien served as General Counsel, Chief Compliance Officer & Secretary of Pear Therapeutics.

07:02 EDT Bio-Techne: Wallingford, CT facility has received ISO 13485:2023 certification - Bio-Techne announced that its Wallingford, CT facility has received ISO 13485:2023 certification for its quality management system, demonstrating the company's commitment to producing products for clinical applications. The company's Wallingford site manufacturers Bio-Techne's cartridge-based Simple Plex immunoassays for its automated Ella multiplexing immunoassay platform, a rapid and hands-free precision biomarker detection system.

06:58 EDT CVS Health CFO Shawn Guertin takes personal leave of absence - In a regulatory filing, CVS Health said that effective October 13, Shawn Guertin, the company's EVP and CFO, has begun a personal leave of absence for unforeseen family medical reasons. In connection with Guertin's leave, the company's Board of Directors appointed Thomas Cowhey, SVP, Corporate Finance, to serve as the company's interim CFO, effective October 13.

06:48 EDT GSK announces CHMP of EMA adopted positive opinion of Jemperli - GSK announced the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has adopted a positive opinion recommending approval of Jemperli in combination with carboplatin-paclitaxel, for the treatment of adult patients with mismatch repair deficient/microsatellite instability-high, MSI-H, primary advanced or recurrent endometrial cancer and who are candidates for systemic therapy. Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: "We are pleased with this positive CHMP opinion and the potential for dostarlimab with chemotherapy to treat patients with this very challenging form of endometrial cancer. If approved, dostarlimab plus chemotherapy will be the first new treatment option in decades for these patients in the European Union, offering long-awaited new hope for improved long-term outcomes. This opinion further reinforces our confidence in dostarlimab's important role in the immuno-oncology treatment landscape."

06:37 EDT Vertex Energy names BofA Securities as strategic financial advisor - Vertex Energy announced that it has formally named BofA Securities as Vertex's strategic financial advisor to assist with the Company's renewable fuels and sustainable products growth strategy. During this engagement, the Company expects to review various potential strategic transaction opportunities aimed at strengthening the balance sheet to support growth acceleration and asset development in line with the Company's forward trajectory as an energy transition company. There can be no assurance that this process will result in any transaction. Vertex has not set a timetable for the completion of this process and does not intend to comment further unless or until the Board of Directors has approved a definitive course of action, or it is determined that other disclosure is necessary or appropriate.

06:33 EDT Newmont announces end of strike at Penasquito Mine in Mexico - Newmont announces it has reached a definitive agreement with the National Union of Mine, Metal, and Allied Workers of the Mexican Republic to end the strike initiated by the Union on June 7, 2023, at the company's Penasquito mine located in the Mexican state of Zacatecas. On October 13, 2023, Newmont and the Union submitted the Agreement to the Mexican Labor Court, which gave its approval, thus ending the strike. The strike was initiated by the Union demanding the company pay additional profit sharing, equivalent to double the amount agreed upon one year ago, along with other alleged violations of the Collective Bargaining Agreement. Key terms of the Agreement include: Newmont will not pay any additional incremental profit sharing for 2022. This was the basis for the strike, and the profit sharing paid by the company this year fully complied with Mexican law and the Collective Bargaining Agreement. If, as a consequence of the strike, the Penasquito mine reports no profit in 2023, then Newmont agrees to pay an additional bonus in Q2 next year, equivalent to two months' wages as the company recognizes the hardship employees have experienced given the duration of the strike. Newmont will pay employees a fixed amount, roughly equivalent to 60% of wages lost, since the strike began on June 7, 2023. This payment is intended to mitigate the financial impact that the strike, initiated by the Union, has had on the company's workforce. In addition, as part of the separate, annual wage negotiations under the Collective Bargaining Agreement, Newmont and the Union have agreed to an 8% wage increase, in line with Mexican mining industry wage increases for 2023. These wage negotiations were not part of the Union's claims as grounds for taking the strike action. Newmont's priority is to safely return the workforce to this Tier 1 operation while ensuring an orderly ramp-up in production. It is expected to take several weeks to achieve stable production levels and a status update will be provided during the company's Q3 earnings call on October 26, 2023.

06:18 EDT AstraZeneca says Tagrisso plus chemo sNDA granted Priority Review in U.S. - AstraZeneca's supplemental New Drug Application, or sNDA, for Tagrisso in combination with chemotherapy has been accepted and granted Priority Review in the U.S. for the treatment of adult patients with locally advanced or metastatic epidermal growth factor receptor-mutated non-small cell lung cancer, or NSCLC, the company announced.

06:08 EDT Aimfinity Investment Corp. I enters merger agreement with Docter Inc. - Aimfinity Investment Corp. I and Docter Inc., a Taiwanese non-invasive blood glucose watch developer, announced that they have entered a definitive merger agreement pursuant to which a newly established subsidiary of Aimfinity will become a publicly listed company combining Aimfinity and Docter upon the closing of the transaction contemplated therein. Upon closing, the combined company expects to list its ordinary shares on Nasdaq. As provided in the Merger Agreement, the merger consideration is $60,000,000, payable by newly-issued shares of the Combined Company valued at $10.00 per share. Additional earnout shares may be issuable to Docter stockholders after closing, upon achievement of certain sales targets in 2024 and 2025. Following the closing, assuming no redemption by existing public shareholders of Aimfinity, the Aimfinity shareholders will have approximately 51.92% equity interest in the Combined Company and the Docter Stockholders will have approximately 48.08% equity interest in the Combined Company. If, however, there is a maximum redemptions of existing public shareholders of Aimfinity resulting in remaining balance of trust account of $5,000,000, the Aimfinity shareholders will have approximately 29.45% equity interest in the Combined Company and the Docter stockholders will have approximately 70.55% equity interest in the Combined Company. The boards of directors of both Docter and Aimfinity have unanimously approved the Proposed Transaction, which is expected to be completed in the first quarter of 2024, subject to, among other things, approval by the Aimfinity shareholders and the Docter stockholders respectively, and satisfaction of the conditions provided in the Merger Agreement, including regulatory approvals and other customary closing conditions, including a registration statement in connection with the Proposed Transaction being declared effective by the U.S. SEC and the listing application being approved by the Nasdaq Capital Markets LLC.

06:05 EDT Establishment Labs receives FDA clearance for Motiva Flora Tissue Expander - Establishment Labs Holdings announced that the FDA has granted 510k clearance for the Motiva Flora SmoothSilk Tissue Expander. The Flora SmoothSilk Tissue Expander offers several proprietary innovations, including Establishment Labs' patented SmoothSilk surface technology. SmoothSilk has been shown to produce the least amount of inflammation and foreign body response compared to other implant surfaces.1 Flora also includes an RFID-enabled, non-magnetic port, labeled as MR Conditional by the FDA. By being magnet-free, Flora avoids the interference that magnets can cause during MRI and may improve the precision of radiation oncology treatment. All other commercially available breast tissue expanders include magnets. In a blinded head-to-head study where patients were randomized to receive Flora in one breast and a U.S. commercially available tissue expander in the other, patients reported significantly higher aesthetic and comfort scores, as well as less breast pain, discomfort, and nipple sensitivity with Flora. Surgeons reported higher satisfaction with lower pole expansion as well as with the footprint created by Flora. The capsule tissue around the Flora expander was thinner and the peri-prosthetic fluid was significantly lower than with the comparative device.

06:02 EDT Ironwood presented data from the Phase II STARS Nutrition program at UEG Week - Ironwood Pharmaceuticals presented positive final data from the company's Phase II STARS Nutrition program during United European Gastroenterology, or UEG, Week. This multicenter study of nine patients was designed to evaluate the safety, pharmacokinetics, and efficacy of apraglutide, an investigational next-generation, long-acting synthetic GLP-2 analog, on intestinal absorption in adult patients who have Short Bowel Syndrome with Intestinal Failure, or SBS-IF, and Colon-in-Continuity, or CIC. Positive interim results from this study were first announced in October 2022. The data from STARS Nutrition were featured at UEG Week during a late-breaker oral presentation titled "The Long-Acting GLP-2 Analog Apraglutide Provides Clinical Benefit For Patients With Short Bowel Syndrome With Intestinal Failure And Colon In Continuity At 52 Weeks." The presentation highlighted that apraglutide had an acceptable safety profile, which was the primary study objective, and that apraglutide improved intestinal absorption as indicated by 50% parenteral support (PS) volume and energy content decrease, resulting in one or more days off PS. PS reduction was observed as early as week four and was maintained until the end of the study. 78% of patients gained one or more days off PS with all patients achieving clinical response.

05:47 EDT T-Mobile, Deutsche Telekom complete 5G Standalone testing - T-Mobile US and Deutsche Telekom Global have completed testing of 5G Standalone, or 5G SA, roaming, leveraging Deutsche Telekom Global Carrier's Security Edge Protection Proxy, or SEPP, to complete the world's first hosted SEPP 5G SA roaming T-Mobile US and Sunrise and a direct SEPP to SEPP interconnect with AIS Thailand. 5G SA roaming grants customers on participating networks the ability to travel internationally and continue accessing the best 5G experience available with 5G SA.

05:44 EDT Rite Aid initiates process under Chapter 11, receives $3.45B in new financnig - Rite Aid announced it has reached an agreement in principle with certain of its senior secured noteholders on the terms of a financial restructuring plan that will allow the company to accelerate its ongoing business transformation. Implementing the contemplated restructuring plan will significantly reduce the company's debt, increase its financial flexibility and enable it to execute on key initiatives. In connection with this, Rite Aid has initiated a voluntary court-supervised process under Chapter 11 of the U.S. Bankruptcy Code. Rite Aid is continuing to deliver healthcare products and services across its retail and online platforms for the nearly one million customers it serves daily. The court-supervised process provides an orderly and efficient forum for Rite Aid to: finalize and build consensus for the agreement in principle the company has reached with certain of its senior secured noteholders; accelerate the company's store footprint optimization plan; implement a proposed transaction under which MedImpact would acquire Elixir Solutions, subject to the outcome of a court-approved marketing process; access additional liquidity and resolve litigation claims in an equitable manner. In connection with this process, Rite Aid has received a commitment for $3.45B in new financing from certain of its lenders. This financing is expected to provide sufficient liquidity to support the Company throughout this process. The company has reached an agreement in principle with certain of its senior secured noteholders on the terms of a financial restructuring that would significantly reduce the Company's debt. Rite Aid intends to use the court-supervised process to finalize the agreement in principle, build additional consensus for the financial restructuring plan it contemplates and implement it as quickly and efficiently as possible. Rite Aid regularly evaluates its store portfolio. In connection with the court-supervised process, the company will continue assessing its footprint and close additional underperforming stores. These efforts will further reduce the company's rent expense and are expected to strengthen its overall financial performance. The Company will also transfer associates at impacted stores to other Rite Aid locations where possible. Rite Aid has entered into an agreement with MedImpact, pursuant to which MedImpact will acquire Rite Aid's Elixir Solutions business. Under the terms of the agreement, MedImpact will serve as the "stalking horse bidder" in a court-supervised sale process under section 363 of the U.S. Bankruptcy Code. Accordingly, the proposed transaction is subject to higher and better offers, court approval and other customary conditions. Elixir Solutions is operating normally and continuing to serve clients, plan sponsors, members and customers as usual. Elixir Insurance is not included in Rite Aid's Chapter 11 process or the proposed transaction with MedImpact, and it is continuing to operate and serve members as usual. Rite Aid and certain of its subsidiaries, including those that comprise Elixir Solutions, have filed voluntary petitions for reorganization under Chapter 11 of the U.S. Bankruptcy Code in the U.S. Bankruptcy Court for the District of New Jersey. Elixir Insurance is not included in the Chapter 11 process. The Company has filed a number of customary motions with the Court seeking authorization to support its operations, including the payment of employee wages, salaries and benefits without interruption. The Company expects to receive court approval for these requests shortly. The company intends to pay vendors and suppliers in full for goods and services provided on or after the filing date.

05:37 EDT Henry Schein reports cybersecurity incident - Henry Schein determined that a portion of its manufacturing and distribution businesses experienced a cybersecurity incident. Henry Schein took precautionary action, including taking certain systems offline and other steps intended to contain the incident, which has led to temporary disruption of some of Henry Schein's business operations. The company is working to resolve the situation as soon as possible. Henry Schein has determined that the practice management software used by its clients has not been disrupted. The company has engaged outside cybersecurity and forensic information technology experts to help investigate any data impact and respond to this situation. Henry Schein also has notified relevant law enforcement authorities.

05:31 EDT Vaalco Energy provides Q3 production, sales volume update - Vaalco Energy provided an operational and financial update, including production and sales volumes for the third quarter and its increased cash and cash equivalents balance as of September 30. The company highlighted: strong operational performance in Gabon, Egypt and Canada continued to drive robust production and sales volumes in Q3; produced nearly 19,000 net revenue interest barrels of oil equivalent per day, or boepd, at the upper end of Vaalco's Q3 guidance range of 17,500 to 19,200 NRI boepd; recorded sales volumes of almost 19,900 NRI boepd, also at higher end of its guidance range of 18,400 to 20,600 NRI BOEPD; completed an additional crude sales lifting in Gabon of about 600,000 gross barrels of oil in the first week of October and grew cash and cash equivalents to over $100M at September 30, more than double cash and cash equivalents as of June 30, 2023.

05:26 EDT BioNTech provides update on Pfizer $0.9B Comirnaty write-offs - Pfizer (PFE), a collaboration partner of BioNTech (BNTX), announced a non-cash charge for inventory write-offs and other charges related to Pfizer of $0.9B. The company has been informed by Pfizer that the majority of the write-offs relate to raw materials, mainly formulation-related lipids, purchased during the pandemic, as well as COVID-19 vaccine doses adapted to other, non-XBB.1.5 variants produced at risk. According to Pfizer, the write-offs do not address Pfizer-BioNTech COVID-19 Vaccine doses adapted to the XBB.1.5 variant, which has been approved and is being marketed in key geographies. BioNTech is evaluating the potential impact of Pfizer's write-offs and other charges related to Comirnaty on the company's financial results. BioNTech's current expectation is that the company is likely to recognize the effect of Pfizer's inventory write-offs and other charges related to Comirnaty in the third quarter of 2023 up to EUR 0.9B, which represents BioNTech's half of the gross profit-sharing agreement with Pfizer. Any such write-offs will reduce the revenues the company would report for 2023. BioNTech expects to release its financial report for the third quarter of 2023 on November 6.